# Innovative approaches to combat antibiotic resistance: integrating CRISPR/Cas9 and nanoparticles against biofilm-driven infections.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12366227</article-id><article-id pub-id-type="pmid">40830872</article-id>
<article-id pub-id-type="publisher-id">4323</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04323-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Innovative approaches to combat antibiotic resistance: integrating CRISPR/Cas9 and nanoparticles against biofilm-driven infections</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Saffari Natanzi</surname><given-names>Abolfazl</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Poudineh</surname><given-names>Mohsen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Karimi</surname><given-names>Elham</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Khaledi</surname><given-names>Azad</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Haddad Kashani</surname><given-names>Hamed</given-names></name><address><email>hamedir2010@gmail.com</email><email>haddadkashani-h@kaums.ac.ir</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03dc0dy65</institution-id><institution-id institution-id-type="GRID">grid.444768.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0612 1049</institution-id><institution>Anatomical Sciences Research Center, Institute for Basic Sciences, </institution><institution>Kashan University of Medical Sciences, </institution></institution-wrap>Kashan, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04waqzz56</institution-id><institution-id institution-id-type="GRID">grid.411036.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 1498 685X</institution-id><institution>Department of Bacteriology and Virology, School of Medicine, </institution><institution>Isfahan University of Medical Sciences, </institution></institution-wrap>Isfahan, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03mwgfy56</institution-id><institution-id institution-id-type="GRID">grid.412266.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1781 3962</institution-id><institution>Department of Nanobiotechnology, Faculty of Biological Science, </institution><institution>Tarbiat Modares University, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03dc0dy65</institution-id><institution-id institution-id-type="GRID">grid.444768.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0612 1049</institution-id><institution>Infectious Diseases Research Center, </institution><institution>Kashan University of Medical Sciences, </institution></institution-wrap>Kashan, Iran </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>486</elocation-id><history><date date-type="received"><day>14</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>5</day><month>8</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The increasing prevalence of antibiotic-resistant bacterial infections is a major global health concern, with biofilms playing a key role in bacterial persistence and resistance. Biofilms provide a protective matrix that limits antibiotic penetration, enhances horizontal gene transfer, and enables bacterial survival in hostile environments. Conventional antimicrobial therapies are often ineffective against biofilm-associated infections, necessitating the development of novel therapeutic strategies. The CRISPR/Cas9 gene-editing system has emerged as a revolutionary tool for precision genome modification, offering targeted disruption of antibiotic resistance genes, quorum sensing pathways, and biofilm-regulating factors. However, the clinical application of CRISPR-based antibacterials faces significant challenges, particularly in efficient delivery and stability within bacterial populations. Nanoparticles (NPs) present an innovative solution, serving as effective carriers for CRISPR/Cas9 components while exhibiting intrinsic antibacterial properties. Nanoparticles can enhance CRISPR delivery by improving cellular uptake, increasing target specificity, and ensuring controlled release within biofilm environments. Recent advances have demonstrated that liposomal CRISPR-Cas9 formulations can reduce <italic>Pseudomonas aeruginosa</italic> biofilm biomass by over 90% in vitro, while gold nanoparticle carriers enhance editing efficiency up to 3.5-fold compared to non-carrier systems. These hybrid platforms also enable co-delivery with antibiotics, producing synergistic antibacterial effects and superior biofilm disruption. Additionally, they can facilitate co-delivery of antibiotics or antimicrobial peptides, further enhancing therapeutic efficacy. This review explores the synergistic integration of CRISPR/Cas9 and nanoparticles in combating biofilm-associated antibiotic resistance. We discuss the mechanisms of action, recent advancements, and current challenges in translating this approach into clinical practice. While CRISPR-nanoparticle hybrid systems hold immense potential for next-generation precision antimicrobial therapies, further research is required to optimize delivery platforms, minimize off-target effects, and assess long-term safety. Understanding and overcoming these challenges will be critical for developing effective biofilm-targeted antibacterial strategies.</p><sec><title>Graphical Abstract</title><p id="Par2">
<graphic position="anchor" xlink:href="12916_2025_4323_Figa_HTML" id="MO1"/></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antibiotic resistance</kwd><kwd>Biofilm</kwd><kwd>CRISPR/Cas9</kwd><kwd>Nanoparticles</kwd><kwd>Gene editing</kwd><kwd>Antibacterial therapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par17">Antibiotic-resistant infections pose a significant threat to global health, with biofilm-associated infections being particularly challenging due to their inherent resistance to conventional antimicrobial therapies [<xref ref-type="bibr" rid="CR1">1</xref>]. Biofilms are structured communities of microorganisms such as bacteria or fungi that adhere to surfaces and are embedded in self-produced extracellular polymeric substances (EPS) [<xref ref-type="bibr" rid="CR2">2</xref>]. This matrix creates microenvironments that can reduce antibiotic efficacy by altering bacterial metabolism and limiting the penetration of antibiotics [<xref ref-type="bibr" rid="CR1">1</xref>]. Antimicrobial resistance in bacterial populations arises via two distinct but often co-occurring mechanisms. The first involves heritable genetic adaptations, such as the acquisition of resistance genes (e.g., bla, mecA, ndm-1) through plasmids or transposons, allowing bacteria to enzymatically degrade antibiotics or evade their binding. In contrast, biofilm-mediated resistance is primarily phenotypic, driven by the protective extracellular polymeric substance (EPS) matrix, reduced metabolic activity of persister cells, and quorum sensing&#x02013;regulated efflux systems. Notably, biofilms can exhibit up to 1000-fold greater tolerance to antibiotics compared to planktonic cells [<xref ref-type="bibr" rid="CR3">3</xref>]. This mechanistic divergence highlights the need for a dual-action approach: CRISPR&#x02013;Cas systems offer precise targeting of genetic resistance determinants, while nanoparticle-based delivery enhances penetration through biofilm barriers&#x02014;together forming a synergistic antimicrobial strategy. The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a natural defense system found in bacteria and archaea that helps them fight viral infections. The CRISPR/Cas9 system is a powerful tool for gene editing, opening new avenues for combating antibiotic resistance. CRISPR/Cas9 allows for precise targeting and modification of specific genetic sequences, offering potential for eradicating antibiotic resistance genes [<xref ref-type="bibr" rid="CR4">4</xref>]. This system consists of two key components: the Cas9 nuclease, which introduces double-strand breaks in DNA, and a guide RNA (gRNA) that directs Cas9 to the specific genomic sequence. By designing gRNAs to target resistance genes, researchers can disrupt these genes, thereby resensitizing bacteria to antibiotics [<xref ref-type="bibr" rid="CR5">5</xref>]. Recent advancements have highlighted the synergistic potential of combining the CRISPR/Cas9 system with nanoparticles to enhance the delivery and efficacy of antimicrobial agents against biofilm-associated infections. Nanoparticles, due to their unique physicochemical properties, can facilitate targeted delivery, improve cellular uptake, and protect genetic material from degradation [<xref ref-type="bibr" rid="CR6">6</xref>]. Various types of nanoparticles, such as lipid-based nanoparticles, polymeric nanoparticles, and metallic nanoparticles, have been explored for this purpose. These carriers can be engineered to possess surface modifications that enhance their interaction with biofilm components, ensuring efficient penetration and delivery of CRISPR/Cas9 constructs directly to the bacterial cells. For instance, liposomal Cas9 formulations reduced P. aeruginosa biofilm biomass by over 90% in vitro [<xref ref-type="bibr" rid="CR7">7</xref>], and CRISPR&#x02013;gold nanoparticle hybrids demonstrated a 3.5-fold increase in gene-editing efficiency while promoting synergistic action with antibiotics [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. This combination strategy not only improves the precision of CRISPR/Cas9 targeting but also overcomes the barriers posed by biofilm matrices, thereby enhancing the treatment outcomes of resistant infections [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Additionally, the use of nanoparticles can facilitate the co-delivery of antibiotics alongside CRISPR/Cas9, creating a multifaceted approach that attacks bacteria through both genetic disruption and traditional antimicrobial mechanisms. This integrated method holds promise for addressing the growing crisis of antibiotic resistance, particularly in chronic and device-associated infections where biofilms are prevalent [<xref ref-type="bibr" rid="CR7">7</xref>]. However, current mono-therapeutic strategies&#x02014;whether based solely on genetic editing or on nanoparticle-mediated delivery&#x02014;often fall short in overcoming the complex barriers of biofilm-associated resistance. Therefore, there is an urgent need for interdisciplinary combinatorial strategies that integrate molecular gene-targeting tools such as CRISPR/Cas with advanced nanocarriers for precise and effective antimicrobial therapy [<xref ref-type="bibr" rid="CR8">8</xref>]. This paper aims to provide an in-depth exploration of the integration of CRISPR/Cas9 technology with nanoparticle-based delivery systems, focusing on their combined efficacy in managing and treating antibiotic-resistant infections associated with biofilms.</p></sec><sec id="Sec2"><title>The antibiotic resistance disaster: a global challenge</title><p id="Par18">Antibiotic resistance represents one of the most urgent threats to global health, food security, and modern development. The rapid emergence and spread of resistant bacteria negatively affect the efficacy of antibiotics, which are crucial for treating bacterial infections. According to the World Health Organization (WHO), antibiotic resistance causes an estimated 700,000 deaths annually, a figure projected to rise dramatically if current trends continue (WHO, 2020). Antibiotic resistance is induced through genetic mutations or the acquisition of resistance genes via horizontal gene transfer. The primary mechanisms include enzymatic degradation or modification where bacteria produce enzymes such as beta-lactamases that deactivate antibiotics [<xref ref-type="bibr" rid="CR12">12</xref>], alteration of target sites through mutations in bacterial proteins that prevent antibiotic binding [<xref ref-type="bibr" rid="CR13">13</xref>], efflux pumps that bacteria use to expel antibiotics before they can exert their effects [<xref ref-type="bibr" rid="CR14">14</xref>], and reduced permeability resulting from changes in the bacterial cell membrane that decrease antibiotic uptake [<xref ref-type="bibr" rid="CR15">15</xref>]. Several factors accelerate the development and spread of antibiotic resistance, including overuse and misuse of antibiotics through inappropriate prescribing, self-medication, and over-the-counter availability [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], agricultural use where antibiotics are used in livestock for growth promotion and disease prevention fostering resistant strains [<xref ref-type="bibr" rid="CR17">17</xref>], poor infection control with inadequate hygiene and sanitation in healthcare settings and communities facilitating the spread of resistant bacteria [<xref ref-type="bibr" rid="CR18">18</xref>], and global travel and trade which increase the dissemination of resistant strains across borders [<xref ref-type="bibr" rid="CR19">19</xref>]. The consequences of antibiotic resistance are profound, leading to increased morbidity and mortality as resistant infections are harder to treat, resulting in longer illnesses and higher death rates [<xref ref-type="bibr" rid="CR20">20</xref>]. It also imposes an economic burden due to higher healthcare costs from prolonged hospital stays, additional tests, and more expensive treatments (Smith &#x00026; Coast, 2013), and threatens medical procedures like surgeries, cancer chemotherapy, and organ transplants, which become riskier without effective antibiotics [<xref ref-type="bibr" rid="CR21">21</xref>]. Addressing this crisis requires a multifaceted approach, including antibiotic stewardship to promote the appropriate use of antibiotics in healthcare and agriculture [<xref ref-type="bibr" rid="CR22">22</xref>], enhanced global monitoring of antibiotic resistance patterns (WHO, 2020), investment in new antibiotics, vaccines, and diagnostic tools [<xref ref-type="bibr" rid="CR23">23</xref>], raising public awareness about the risks of antibiotic misuse, and strengthening hygiene practices, vaccination programs, and infection control measures. Through stewardship, surveillance, research, and education, the spread of resistance can be slowed, preserving the efficacy of existing antibiotics for future generations [<xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec3"><title>Biofilm structure and ultrastructural review of bacterial biofilms</title><p id="Par19">The biofilm structure is highly organized, often displaying a heterogeneous architecture characterized by microcolonies interspersed with water channels that facilitate nutrient distribution and waste removal [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Biofilm formation begins with the adhesion of microorganisms to a surface, followed by the production of EPS, which holds the cells together and anchors the biofilm to the substrate. The process involves multiple stages, starting from initial attachment, irreversible attachment, maturation, and finally dispersion. Biofilms can consist of a single species of bacteria or multiple species, often including fungi and other microorganisms in complex communities. The extracellular matrix, composed primarily of polysaccharides, proteins, and extracellular DNA (eDNA), forms a protective barrier that limits the penetration of antibiotics and plays a pivotal role in maintaining biofilm integrity and resilience. This matrix is not only a physical impediment but also a source of microenvironments within the biofilm, where bacterial cells experience [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. The heterogeneous structure of biofilms creates microenvironments with varying levels of nutrient availability, pH, oxygen, and waste products, which can contribute to the survival of microorganisms even under challenging conditions [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. At the ultrastructural level, bacterial biofilms exhibit a stratified organization. The basal layer, in close contact with the surface, consists of densely packed cells that form strong adhesions via adhesins and pili, contributing to the initial attachment phase. Above this layer, microcolonies develop, often surrounded by a dense EPS matrix that acts as a protective barrier against antibiotics and immune responses [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. The uppermost layers are less densely packed, with cells exhibiting phenotypic heterogeneity, including persister cells that contribute to antibiotic resistance [<xref ref-type="bibr" rid="CR25">25</xref>]. Advanced imaging techniques such as confocal laser scanning microscopy (CLSM) and scanning electron microscopy (SEM) have shown the dynamic and complex nature of biofilm ultrastructure. The intricate architecture and ultrastructural complexity of bacterial biofilms underscore their role in chronic infections and their resilience against antimicrobial treatments. Understanding these structural nuances is critical for developing effective strategies to disrupt biofilm formation and enhance antibiotic efficacy [<xref ref-type="bibr" rid="CR30">30</xref>]. The resistance mechanisms employed by bacteria within biofilms have garnered significant attention due to their role in persistent infections and their ability to circumvent traditional antimicrobial therapies. The development of biofilm-associated resistance involves a variety of mechanisms, including structural barriers, altered metabolic states, genetic adaptation, and intercellular communication. The molecular basis of biofilm resistance is complex, and ongoing research aims to elucidate the key factors involved in this phenomenon [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec4"><title>The importance and mechanism of biofilms in antibiotic resistance</title><p id="Par20">The formation of biofilms allows bacteria to survive in hostile environments, including under the stress of antibiotic treatment. This resistance mechanism is particularly significant in chronic infections and hospital settings, where biofilm-associated infections are prevalent [<xref ref-type="bibr" rid="CR3">3</xref>]. One of the most concerning aspects of biofilms is their ability to contribute to antibiotic resistance. Several mechanisms have been identified by which biofilms enhance bacterial resistance to antibiotics by biofilms. Many antibiotics are less effective against biofilm-associated bacteria because they cannot reach the cells in the inner regions of the biofilm. Within biofilms, bacteria exist in a slower-growing or dormant state. Antibiotics, particularly those targeting cell wall synthesis or protein synthesis, are less effective against slow-growing or dormant cells. As a result, biofilm bacteria can survive even in the presence of therapeutic concentrations of antibiotics [<xref ref-type="bibr" rid="CR31">31</xref>]. The &#x0201c;persisters,&#x0201d; a subset of bacterial cells within biofilms, exhibit a dormant phenotype that is highly resistant to antibiotics. The role of persister cells in biofilm-associated resistance is another critical aspect of the resistance phenotype. Persister cells are a small subpopulation of metabolically inactive or slow-growing cells that can survive exposure to high concentrations of antibiotics. These cells are thought to be present in biofilms as a result of stress-induced dormancy. The mechanisms underlying persister cell formation remain incompletely understood, but several studies suggest that changes in bacterial gene expression, including the upregulation of stress response pathways, are involved [<xref ref-type="bibr" rid="CR32">32</xref>]. The ability of persister cells to endure antimicrobial treatments contributes to the recalcitrance of biofilm infections, as these cells can &#x0201c;wake up&#x0201d; and repopulate the biofilm once the antibiotic pressure is relieved. One of the most significant mechanisms is the upregulation of efflux pumps, which actively expel antibiotics from bacterial cells, reducing the intracellular concentration of the drug. Efflux pumps are often regulated by quorum sensing, a bacterial communication system that involves the release and detection of small signaling molecules. In biofilms, quorum sensing regulates the expression of genes responsible for efflux pump production, as well as other resistance factors, such as oxidative stress response proteins [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Quorum sensing also modulates the production of extracellular matrix components, further promoting biofilm formation and resistance to antimicrobial agents [<xref ref-type="bibr" rid="CR34">34</xref>]. Biofilm-associated bacteria often express higher levels of efflux pumps, which can actively expel antibiotics from bacterial cells, thereby reducing their efficacy. Additionally, biofilms can increase the production of enzymes like &#x003b2;-lactamases that degrade antibiotics [<xref ref-type="bibr" rid="CR35">35</xref>]. The physical and chemical structure of the biofilm plays a crucial role in protecting bacterial cells from antimicrobial agents. In addition to the physical barrier provided by the extracellular matrix, biofilm-forming bacteria are equipped with a range of molecular mechanisms that enhance their resistance to antimicrobial agents. Biofilms provide an environment that facilitates genetic exchange among microorganisms. Horizontal gene transfer (HGT), including the transfer of antibiotic resistance genes, is more frequent within biofilms. This can lead to the rapid spread of resistance traits among bacterial populations. The genetic diversity of bacteria within biofilms also plays a pivotal role in the development of resistance. Biofilm environments are conducive to horizontal gene transfer, allowing for the exchange of antibiotic resistance genes among bacterial cells. The dense, cooperative structure of biofilms facilitates the transfer of plasmids, transposons, and other mobile genetic elements, which may carry resistance determinants. This genetic exchange not only accelerates the acquisition of resistance but also results in the establishment of stable, resistant subpopulations within the biofilm [<xref ref-type="bibr" rid="CR36">36</xref>]. Furthermore, biofilm formation itself has been shown to induce genetic mutations that contribute to the development of resistance, particularly in response to prolonged antibiotic exposure [<xref ref-type="bibr" rid="CR37">37</xref>]. Several recent studies have focused on the role of the biofilm&#x02019;s microenvironment in modulating antibiotic resistance. The physical characteristics of biofilms, including their thickness and density, influence the diffusion of antimicrobial agents and create microenvironments with reduced drug penetration. This limited access to antibiotics enhances the persistence of bacteria within biofilms, even in the presence of otherwise effective treatments [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Moreover, biofilms in vivo are frequently exposed to sub-lethal concentrations of antibiotics, which may induce adaptive resistance mechanisms such as the activation of efflux pumps, DNA repair pathways, and changes in membrane permeability. These adaptive responses allow bacteria to survive under conditions that would otherwise be fatal [<xref ref-type="bibr" rid="CR38">38</xref>]. Biofilm-associated infections are frequently encountered in clinical settings, particularly among patients with indwelling medical devices such as catheters, prosthetic joints, and cardiac valves. These abiotic surfaces facilitate microbial adhesion and subsequent biofilm development, contributing to persistent infections that exhibit a high degree of tolerance to conventional antimicrobial therapies. Key bacterial species implicated in these infections include <italic>Staphylococcus aureus</italic>, <italic>Pseudomonas aeruginosa</italic>, <italic>Escherichia coli</italic>, and <italic>Enterococcus</italic> spp. Research about biofilm-targeting strategies has grown in recent years, aiming to develop treatments that can either prevent biofilm formation, disrupt established biofilms, as well as methods to inhibit the initial attachment of bacteria or block the signaling pathways that regulate biofilm formation (e.g., quorum sensing inhibitors) are under investigation. Enzymes that degrade components of the EPS matrix, such as DNases or polysaccharide-degrading enzymes, can enhance the effectiveness of antibiotics by allowing better penetration into the biofilm. Combining antibiotics with agents that disrupt biofilms or enhance antibiotic penetration is a promising strategy. This approach could reduce the likelihood of resistance development by targeting multiple aspects of biofilm-associated bacterial survival. Nanomaterials such as silver nanoparticles or nanostructured surfaces are being explored for their ability to disrupt biofilms and enhance antibiotic efficacy [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Bacteriophages, viruses that infect and kill bacteria, are being investigated for their potential to target and disrupt biofilms without promoting antibiotic resistance [<xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref>]. The ability of bacteria within biofilms to resist antibiotic treatment, evade immune responses, and exchange resistance genes makes biofilm-associated infections particularly difficult to treat. Understanding the mechanisms underlying biofilm formation and resistance is essential for the development of more effective treatment strategies. Continued research into biofilm biology and innovative therapeutic approaches will be key in addressing the growing challenge of antibiotic resistance [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Biofilm-associated antibiotic resistance represents a complex and multifactorial challenge in both clinical and environmental contexts. Understanding the underlying mechanisms is crucial for developing effective therapeutic strategies [<xref ref-type="bibr" rid="CR43">43</xref>]. Understanding the mechanisms of biofilm resistance has significant clinical implications, particularly for the treatment of chronic and recurrent infections. The recalcitrance of biofilm-associated bacteria to antibiotics necessitates the development of novel therapeutic strategies aimed at disrupting biofilm formation, enhancing drug penetration, or targeting specific resistance mechanisms. Recent advances have explored the use of enzymatic agents that degrade the extracellular matrix, as well as the development of compounds that inhibit quorum sensing or efflux pump activity [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Additionally, combining traditional antibiotics with agents that disrupt biofilm structure or function may improve treatment outcomes and help overcome the challenges associated with biofilm-associated infections [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR38">38</xref>].</p></sec><sec id="Sec5"><title>CRISPR-Cas system</title><p id="Par21">The CRISPR-Cas system is a revolutionary genetic tool that has reshaped the landscape of molecular biology and genetic engineering. Originally discovered in bacteria and archaea as an adaptive immune mechanism, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and its associated protein, Cas (CRISPR-associated proteins), have been repurposed for genome editing in diverse organisms. The CRISPR/Cas system roles in microbial defense involve storing segments of viral DNA in the form of CRISPR sequences and using these sequences to guide the Cas proteins to target and cleave foreign DNA during subsequent infections [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. The discovery of the programmable nature of CRISPR-Cas9, in particular, has enabled precise modifications to the genome of various organisms (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), ushering in an era of unprecedented genetic manipulation [<xref ref-type="bibr" rid="CR45">45</xref>]. The gene-editing system consists of two primary components: the Cas9 endonuclease and a guide RNA (gRNA). The Cas9 protein introduces double-strand breaks (DSBs) in the target DNA at a precise location defined by the gRNA. Once the DSB occurs, the bacterial repair mechanisms, such as non-homologous end joining (NHEJ) or homology-directed repair (HDR), attempt to repair the break, often resulting in gene knockouts or insertions that can disrupt biofilm-related processes. This precise targeting ability enables researchers to investigate the molecular mechanisms underpinning biofilm formation, maintenance, and eradication [<xref ref-type="bibr" rid="CR46">46</xref>]. This precision allows researchers to cut and edit specific genes, making it an invaluable tool for genetic engineering and research. When the DNA is cut by Cas9, the cell attempts to repair the break through one of two pathways: non-homologous end joining (NHEJ) or homology-directed repair (HDR). NHEJ is error-prone and often introduces small insertions or deletions (indels) that can disrupt gene function, while HDR can be used for precise edits if a donor DNA template is provided [<xref ref-type="bibr" rid="CR47">47</xref>]. This system has been harnessed not only for gene knockout experiments but also for more complex tasks, such as gene insertion, correction of mutations, and even gene activation or repression, depending on the modifications made to the Cas9 protein or the RNA guide [<xref ref-type="bibr" rid="CR45">45</xref>]. The applications of CRISPR-Cas9 have revolutionized molecular biology and genetic research, including in fields such as agriculture, medicine, and biotechnology. It has enabled the development of genetically modified organisms (GMOs) with enhanced traits, such as crops resistant to diseases or environmental stressors, as well as the potential for treating genetic diseases through gene therapy. In human medicine, CRISPR-Cas9 has shown promise for correcting genetic defects at the DNA level, with ongoing research into its potential for treating conditions like cystic fibrosis, sickle cell anemia, and muscular dystrophy [<xref ref-type="bibr" rid="CR47">47</xref>]. However, ethical concerns, including the potential for off-target effects and germline editing, remain significant hurdles that need to be addressed as the technology continues to evolve [<xref ref-type="bibr" rid="CR48">48</xref>]. In recent years, improvements to the CRISPR-Cas9 system have been made, including the development of more precise and efficient versions like CRISPR-Cas12 and CRISPR-Cas13, which target DNA and RNA, respectively. These advancements have expanded the utility of CRISPR beyond genome editing to other applications such as RNA editing and diagnostics, offering even more potential for biomedical and therapeutic innovations [<xref ref-type="bibr" rid="CR49">49</xref>].
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Representative CRISPR/Cas9-nanoparticle delivery systems with antibacterial, anti-inflammatory, or biofilm-relevant applications</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Nanoparticle platform</th><th align="left">CRISPR-Cas9 form</th><th align="left">Target cells/organism</th><th align="left">Target gene</th><th align="left">Model</th><th align="left">Application</th><th align="left">Key findings</th><th align="left">Ref</th></tr></thead><tbody><tr><td align="left"><bold>Polymeric NPs</bold></td><td align="left">RNPs</td><td align="left"><italic>Staphylococcus aureus</italic> (MRSA)</td><td align="left"><bold>mecA</bold></td><td align="left">In vitro</td><td align="left">Antibacterial (resistance)</td><td align="left">Disrupted <italic>mecA</italic> gene; suppressed resistance to methicillin; restored antibiotic susceptibility</td><td align="left"> [<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left"><bold>PEI Magnetic NPs</bold></td><td align="left">Plasmid DNA</td><td align="left">HEK293 cells</td><td align="left"><bold>TLR3</bold></td><td align="left">In vitro</td><td align="left">Immunomodulatory/host defense</td><td align="left">Magnetic field-assisted CRISPR delivery enabled site-specific genome editing; potential application in modulating host defense genes against infection</td><td align="left"> [<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td align="left"><bold>Lipid-based NPs</bold></td><td align="left">Cas9 mRNA&#x02009;+&#x02009;sgRNA</td><td align="left">BMDMs/C57BL/6 mice</td><td align="left"><bold>NLRP3</bold></td><td align="left">In vitro/in vivo</td><td align="left">Anti-inflammatory/sepsis control</td><td align="left">70.2% NLRP3 knockout in vitro; modulated macrophage inflammation pathways; potentially reducing inflammatory damage in infections</td><td align="left"> [<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td align="left"><bold>Lipid-based NPs</bold></td><td align="left">Cas9 mRNA&#x02009;+&#x02009;sgRNA</td><td align="left">HEK293 endothelial cells</td><td align="left"><bold>ICAM-2</bold></td><td align="left">In vivo</td><td align="left">Biofilm penetration (vascular)</td><td align="left">Endothelial targeting improved CRISPR delivery; may enhance vascular targeting of antimicrobials</td><td align="left"> [<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left"><bold>Gold-lipid hybrid NPs</bold></td><td align="left">Plasmid DNA</td><td align="left">Melanoma&#x02009;+&#x02009;Bacteria models</td><td align="left"><bold>PLK-1</bold></td><td align="left">In vitro/in vivo</td><td align="left">Dual antibacterial/antitumor</td><td align="left">Photothermal CRISPR system disrupted cell proliferation and potentially sensitized microenvironments to therapy</td><td align="left"> [<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left"><bold>Lipidoid NPs</bold></td><td align="left">RNPs</td><td align="left">HeLa-DsRed cells (biofilm test)</td><td align="left"><bold>GFP reporter</bold></td><td align="left">In vivo</td><td align="left">CRISPR delivery validation</td><td align="left">Achieved&#x02009;~&#x02009;70% knockout with low toxicity; relevant for CRISPR-based biosensors or delivery in biofilm-like environments</td><td align="left"> [<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left"><bold>Polymeric NPs</bold></td><td align="left">Plasmid DNA</td><td align="left">HFD-induced diabetic mice</td><td align="left"><bold>NE (elastase)</bold></td><td align="left">In vivo</td><td align="left">Inflammatory/metabolic infection</td><td align="left">Knockout of neutrophil elastase reduced inflammation; improved insulin sensitivity, suggesting infection-linked inflammation modulation</td><td align="left"> [<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left"><bold>Core&#x02013;shell Fe/PEI NPs</bold></td><td align="left">Plasmid DNA</td><td align="left">Porcine fibroblasts</td><td align="left"><bold>H11</bold></td><td align="left">In vitro</td><td align="left">Gene delivery platform</td><td align="left">3.5&#x02009;&#x000d7;&#x02009;improvement in delivery over lipofection; potential for CRISPR editing in antimicrobial peptide research</td><td align="left"> [<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left"><bold>Polymeric NPs</bold></td><td align="left">Plasmid DNA</td><td align="left">HEK293&#x02009;+&#x02009;HeLa</td><td align="left"><bold>GFP/iRFP</bold></td><td align="left">In vitro</td><td align="left">CRISPR validation in cell platforms</td><td align="left">70% knockout; useful for building infection reporters or delivery optimization in biofilm models</td><td align="left"> [<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec6"><title>Mechanism of action of the CRISPR-Cas9 system</title><p id="Par22">The sgRNA is engineered to be complementary to a target DNA sequence and directs Cas9 to that sequence for cleavage. The precise targeting is facilitated by the presence of a protospacer adjacent motif (PAM) in the DNA sequence, which is required for Cas9 recognition (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The PAM sequence, typically &#x0201c;NGG&#x0201d; in <italic>Streptococcus pyogenes</italic> Cas9, serves as a critical determinant for the binding of Cas9 to the target DNA and the subsequent DNA cleavage event [<xref ref-type="bibr" rid="CR59">59</xref>]. Upon recognition of the PAM sequence, the Cas9 protein undergoes a conformational change, which allows it to unwind the DNA around the target sequence. The sgRNA then binds to the complementary DNA strand, forming a DNA-RNA hybrid structure. This binding is essential for the specificity of the system, as the Cas9 protein will only activate its nuclease activity when the guide RNA is fully paired with the target DNA [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Cas9 has two distinct nuclease domains: The RuvC and HNH domains, which play complementary roles in cleaving the DNA. The HNH domain cleaves the strand of the DNA that is complementary to the guide RNA, while the RuvC domain cleaves the non-complementary strand, creating a double-strand break. This precise, staggered cleavage generates sticky ends that can be repaired through the cell's repair mechanisms, leading to either random mutations or targeted insertions, depending on the repair pathway activated [<xref ref-type="bibr" rid="CR61">61</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Mechanisms of CRISPR-Cas9 in combating bacterial biofilms: <bold>a</bold> Resistance gene disruption: CRISPR-Cas9 targets antibiotic resistance genes via sequence-specific guide RNA (gRNA), inducing double-strand breaks at the protospacer adjacent motif (PAM) site. Cas9 cleavage disrupts resistance gene integrity, restoring bacterial susceptibility. <bold>b</bold> Quorum sensing inhibition: CRISPR-Cas9 disrupts quorum sensing (QS) by targeting transcriptional regulators (e.g., LuxR, BMIR proteins), blocking autoinducer-mediated signaling and biofilm coordination. <bold>c</bold> EPS degradation: CRISPR editing of genes encoding extracellular polymeric substances (EPS), such as phosphorylated cellulose (Pel polysaccharide), destabilizes the biofilm matrix, enhancing structural collapse. <bold>d</bold> Suppressing horizontal gene transfer: CRISPR-Cas systems degrade foreign DNA (e.g., plasmids) carrying resistance genes, preventing horizontal gene transfer (HGT) within biofilm communities</p></caption><graphic xlink:href="12916_2025_4323_Fig1_HTML" id="MO2"/></fig></p><p id="Par23">Once the DSB is induced, the cell responds with one of two major DNA repair mechanisms: non-homologous end joining (NHEJ) or homology-directed repair (HDR). NHEJ is the predominant repair pathway, particularly in mammalian cells. It is an error-prone mechanism that directly ligates the broken ends of DNA without a homologous template, often leading to insertions or deletions (indels) at the break site. These indels can cause frameshift mutations, effectively disrupting the targeted gene&#x02019;s function. Alternatively, HDR is a more accurate repair mechanism that utilizes a homologous template to repair the break. This template could be provided exogenously, such as a donor plasmid or a single-stranded oligodeoxynucleotide (ssODN), and can be used for precise gene edits or insertions. HDR is less efficient in non-dividing cells, which makes it challenging for precise editing in certain tissues, but is still invaluable when precise gene editing is required [<xref ref-type="bibr" rid="CR62">62</xref>]. The precise action of CRISPR-Cas9 in editing genomes also hinges on its specificity. A major limitation of the system is its propensity for off-target effects, where Cas9 induces DNA breaks at unintended genomic locations that have sequence homology to the target sequence. Off-target cleavage typically occurs when the sgRNA binds to a similar but non-identical sequence elsewhere in the genome, especially when the off-target sequence contains a PAM sequence [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. These off-target effects could lead to unwanted genetic mutations or disruptions in functional genes, which could have unintended consequences, particularly in therapeutic applications. To minimize such risks, several strategies have been developed to increase the specificity of the CRISPR-Cas9 system. One of the most notable approaches involves the engineering of high-fidelity Cas9 variants that exhibit reduced off-target cleavage while maintaining editing efficiency. These include Cas9 variants such as eSpCas9, HypaCas9, and SpCas9-HF1, all of which have been shown to reduce off-target activity significantly without compromising the system&#x02019;s on-target editing efficacy [<xref ref-type="bibr" rid="CR60">60</xref>]. Additionally, research into alternative CRISPR-associated proteins, such as Cpf1 (now known as Cas12), has shown promise for improving target specificity. Cas12 has distinct features, such as a different PAM sequence requirement (&#x0201c;TTTN&#x0201d;), and an ability to generate staggered cuts, which may reduce off-target activity and expand the range of editable loci [<xref ref-type="bibr" rid="CR63">63</xref>]. The applications of CRISPR-Cas9 extend beyond basic genome editing to therapeutic and biotechnological realms. The ability to induce precise gene modifications, correct genetic mutations, or knock out genes has profound implications for the treatment of genetic disorders, such as sickle cell anemia and Duchenne muscular dystrophy [<xref ref-type="bibr" rid="CR64">64</xref>]. Furthermore, CRISPR-Cas9 enables functional genomics, allowing researchers to systematically study gene function by creating knockout or knock-in cell lines, animal models, and organoids. Despite its immense potential, challenges such as delivery mechanisms, off-target effects, and efficiency of HDR in non-dividing cells remain areas of active research [<xref ref-type="bibr" rid="CR65">65</xref>]. Recent improvements in CRISPR technology, including advanced delivery techniques and the development of next-generation CRISPR-Cas systems, are addressing some of these limitations and will likely accelerate the therapeutic and industrial applications of genome editing [<xref ref-type="bibr" rid="CR59">59</xref>].</p></sec><sec id="Sec7"><title>The CRISPR-Cas system and biofilm-related antibacterial resistance</title><p id="Par24">The CRISPR-Cas system has gained significant attention for its potential in antimicrobial strategies, particularly in targeting antibiotic-resistant bacterial populations within biofilms. One of the main reasons biofilm-associated bacteria exhibit increased antibiotic resistance is due to limited drug penetration, altered metabolic states, and horizontal gene transfer (HGT), which facilitates the spread of resistance determinants [<xref ref-type="bibr" rid="CR7">7</xref>]. The CRISPR-Cas system plays a dual role in biofilm-related resistance: while it can function as a defense mechanism against phages and plasmids carrying antibiotic resistance genes, it also influences biofilm formation through regulatory pathways [<xref ref-type="bibr" rid="CR17">17</xref>]. CRISPR-Cas9 technology, originally discovered as a bacterial immune system against viral infections, has rapidly evolved as a powerful tool for genome editing, with promising applications in combating antibiotic resistance. One of the promising applications of CRISPR-Cas9 in this field is its ability to specifically target and disrupt antibiotic resistance genes, thereby restoring bacterial susceptibility to antibiotics. Recent studies have demonstrated the ability of CRISPR-Cas9 to target and remove resistance genes from the genomes of pathogenic bacteria. For example, one study successfully utilized CRISPR-Cas9 to cleave the mcr-1 gene, which confers resistance to colistin, in urgent need for novel antimicrobial Escherichia coli strains. This approach effectively restored the bacteria&#x02019;s sensitivity to colistin, a last-resort antibiotic, showcasing CRISPR-Cas9&#x02019;s potential to reverse antimicrobial resistance (AMR) [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. Additionally, CRISPR-Cas9 has been applied to target and eliminate plasmids carrying antibiotic resistance genes, such as extended-spectrum beta-lactamase (ESBL) genes, in Klebsiella pneumoniae and Pseudomonas aeruginosa, further proving its ability to reverse resistance mechanisms [<xref ref-type="bibr" rid="CR68">68</xref>]. Moreover, CRISPR-Cas9 has been adapted for use in gene drives, a system that ensures the inheritance of specific genes in a population. Researchers have explored the use of CRISPR-based gene drives to target resistance genes across bacterial populations. This strategy has shown promise in preventing the spread of antibiotic resistance in clinical and environmental settings [<xref ref-type="bibr" rid="CR69">69</xref>]. One of the main advantages of using CRISPR-Cas9 over traditional antibiotic therapies is its precision; while antibiotics indiscriminately kill both pathogenic and beneficial bacteria, CRISPR-Cas9 can specifically target resistance genes without affecting the surrounding microbial community, minimizing collateral damage to the microbiome [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. The widespread and clinical application of the CRISPR system still faces challenges, with the most significant challenge being the delivery of CRISPR complex components. Issues such as delivery efficiency, particularly in the context of human infections, and the potential for off-target effects need to be addressed. The design of safe and effective delivery systems, such as viral vectors or nanoparticles, is critical for successful clinical application [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Additionally, there are concerns about the potential for resistance to CRISPR-Cas9 systems themselves, as bacteria may evolve mechanisms to resist CRISPR-mediated genome editing [<xref ref-type="bibr" rid="CR70">70</xref>]. Despite these hurdles, the application of CRISPR-Cas9 systems represents a transformative approach in the fight against antibiotic resistance. Ongoing research and clinical trials are crucial to overcoming these challenges and unlocking the full potential of CRISPR-based therapies to combat resistant infections [<xref ref-type="bibr" rid="CR71">71</xref>]. Studies have shown that certain CRISPR-Cas systems directly regulate biofilm formation. For example, Type I and Type II CRISPR-Cas systems can modulate quorum sensing (QS) pathways, which are critical for biofilm development. In some bacteria, the disruption of CRISPR-Cas components has been linked to enhanced biofilm formation, suggesting that CRISPR interference can downregulate genes associated with biofilm stability. Conversely, biofilm-forming bacteria often exhibit reduced CRISPR activity, allowing them to acquire foreign genetic material, including antibiotic resistance genes, via HGT [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR72">72</xref>].</p></sec><sec id="Sec8"><title>CRISPR-based strategies for biofilm eradication</title><p id="Par25">Because biofilm-associated resistance has created many challenges, researchers have explored CRISPR-based approaches to disrupt biofilms and re-sensitize bacteria to antibiotics. CRISPR-Cas9 and CRISPR-Cas3 nucleases have been employed to selectively degrade antibiotic resistance genes in biofilm-embedded bacteria, leading to increased susceptibility to conventional antibiotics [<xref ref-type="bibr" rid="CR44">44</xref>]. Additionally, engineered phage-delivered CRISPR systems can selectively lyse biofilm-forming pathogens by targeting essential survival genes. These strategies have shown promising results against clinically relevant pathogens, including <italic>Pseudomonas aeruginosa</italic>, <italic>Escherichia coli</italic>, and <italic>Staphylococcus aureus</italic> [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Recent advancements have also explored CRISPR-guided antimicrobials, wherein programmable CRISPR systems induce targeted double-stranded DNA breaks within resistance genes, effectively eliminating resistant subpopulations from biofilms. Additionally, the combination of CRISPR-based disruption with conventional antibiotics has demonstrated synergistic effects, significantly enhancing bacterial clearance [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR61">61</xref>].</p></sec><sec id="Sec9"><title>Mechanisms of CRISPR/Cas9 editing in biofilm control</title><p id="Par26">In the context of biofilm control, CRISPR/Cas9 can be used to manipulate several key genetic pathways that regulate biofilm formation. The CRISPR/Cas9 system is guided by RNA molecules to specific DNA sequences, often those that regulate the synthesis of extracellular polymeric substances (EPS), which form the matrix of the biofilm. For example, in Staphylococcus aureus, the icaA gene encodes an enzyme involved in the biosynthesis of PIA, a key component of the biofilm matrix. Disrupting icaA via CRISPR/Cas9 results in reduced biofilm formation and impaired bacterial adhesion, a crucial process for biofilm establishment [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. One of the central mechanisms by which biofilms are formed is quorum sensing (QS), a process by which bacteria communicate to regulate group behaviors such as biofilm formation, virulence, and antibiotic resistance. In Pseudomonas aeruginosa, the las and rhl QS systems are vital for biofilm development. These systems involve the production and detection of signaling molecules, which regulate the expression of genes involved in biofilm formation and antibiotic resistance. CRISPR/Cas9 can be used to knock out key genes in these pathways, such as lasR, rhlR, and luxR, to prevent QS and biofilm formation. By targeting these genes, the system could effectively reduce biofilm biomass and make bacterial populations more susceptible to antibiotics [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Another important target is the cyclic-di-GMP signaling pathway. Cyclic-di-GMP is a second messenger molecule that plays a critical role in the regulation of biofilm formation in many bacteria. High levels of cyclic-di-GMP promote biofilm formation, while low levels encourage planktonic growth. Genes like pelA, which encode enzymes involved in cyclic-di-GMP synthesis, are key targets for CRISPR/Cas9 editing. By knocking out or downregulating these genes, researchers have successfully reduced biofilm formation in Pseudomonas aeruginosa. This approach can also be extended to other bacteria where cyclic-di-GMP is involved in biofilm regulation, such as Escherichia coli [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>].</p></sec><sec id="Sec10"><title>Engineering CRISPR/Cas9 for biofilm disruption</title><p id="Par27">For the efficient application of CRISPR/Cas9 in biofilm-targeting strategies, the delivery of CRISPR components into biofilm-embedded bacteria presents a significant challenge. Biofilms act as physical barriers, and the dense EPS matrix often limits the penetration of genetic material, including CRISPR/Cas9 constructs. Various strategies have been explored to overcome this limitation. One approach is the use of nanoparticles or liposomes to deliver CRISPR components (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). These carriers can penetrate biofilm matrices, facilitate the uptake of plasmid DNA or CRISPR/Cas9 complexes, and enhance gene editing efficacy [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. Additionally, bacteriophage-mediated delivery has shown promise in overcoming delivery barriers. Engineered bacteriophages that carry CRISPR/Cas9 components can specifically target and infect bacterial cells within biofilms, thus delivering the gene-editing machinery directly to the desired location [<xref ref-type="bibr" rid="CR69">69</xref>]. Phage-based CRISPR systems have been successfully used to edit genes in <italic>Klebsiella pneumoniae</italic> biofilms, offering a targeted and efficient means of biofilm disruption. Phage-based CRISPR delivery may also offer reduced cytotoxicity to surrounding host cells, making it an attractive strategy for clinical applications [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. In addition to plasmid-based or phage-based delivery, some studies have explored electroporation and other physical methods to facilitate the uptake of CRISPR/Cas9 components in biofilm-forming bacteria. These techniques can increase the permeability of bacterial cell membranes, allowing the introduction of CRISPR plasmids or proteins into biofilm-associated bacteria [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>Engineered nanoparticle platform for CRISPR-Cas9 delivery: mechanisms and applications in biofilm eradication and resistance gene suppression. The figure illustrates multi-purpose nanoparticles vacillating between lipid-based polymeric nanoparticles, such as PLGA and chitosan, and inorganic nanoparticles, such as Au and iron oxide, all types of delivery systems for CRISPR-Cas9 into bacterial biofilms. Nanoparticles scatter across the extracellular polymeric matrix while being taken up by bacterial cells through the receptor-mediated or clathrin/caveolin-dependent endocytosis pathway [<xref ref-type="bibr" rid="CR79">79</xref>]. Following uptake, the CRISPR-Cas9 RNPs are released via endosomal escape mechanisms [<xref ref-type="bibr" rid="CR80">80</xref>], allowing for genome editing</p></caption><graphic xlink:href="12916_2025_4323_Fig2_HTML" id="MO3"/></fig></p></sec><sec id="Sec11"><title>Quorum sensing inhibition and biofilm disruption</title><p id="Par28">Quorum sensing (QS) is a bacterial communication system that regulates biofilm formation and antibiotic resistance. CRISPR-Cas9 has been employed to disrupt QS-regulated genes, such as <italic>luxS</italic>, <italic>lasI</italic>, and <italic>rhlR</italic>, leading to biofilm dispersal and increased bacterial susceptibility to antimicrobials. Nanoparticle formulations enhance this strategy by enabling precise delivery and controlled release of CRISPR-Cas9 components within biofilm structures. Recent studies have highlighted the efficacy of NP-CRISPR systems in QS inhibition, effectively weakening biofilm resilience [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec12"><title>Direct eradication of biofilm-forming bacteria</title><p id="Par29">Beyond targeting antibiotic resistance genes and QS pathways, CRISPR-Cas9 can be programmed to disrupt essential biofilm-associated genes. Genes involved in adhesion (<italic>fimH</italic>, <italic>bap</italic>) and EPS production (<italic>psl</italic>, <italic>pel</italic>, <italic>icaA</italic>) are prime targets for biofilm eradication [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. NP-based CRISPR systems allow targeted gene knockouts, resulting in structural destabilization and enhanced antimicrobial penetration. This strategy has shown significant promise in reducing biofilm biomass and restoring bacterial clearance by antibiotics and host immune defenses. Nanoparticle-mediated CRISPR-Cas9 delivery presents a revolutionary approach for tackling biofilm-associated antibiotic resistance. By ensuring precise targeting of resistance genes, quorum sensing pathways, and biofilm integrity, NP-CRISPR strategies hold great potential for clinical applications. However, challenges such as delivery efficiency, immune responses, and scalability need to be addressed for translational success. Future research should focus on optimizing nanoparticle formulations, enhancing bacterial specificity, and exploring combination therapies with existing antimicrobials. The integration of NP-CRISPR technology with other antimicrobial strategies may pave the way for next-generation biofilm control and infection management [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR81">81</xref>].</p></sec><sec id="Sec13"><title>Relationships between the CRISPR-Cas system and antibiotic resistance</title><p id="Par30">The CRISPR-Cas system has shown a complex relationship with antibiotic resistance, as it not only serves as a defense against phage attacks but also influences the dynamics of horizontal gene transfer (HGT) and the spread of antibiotic resistance genes (ARGs). The role of the CRISPR-Cas system in antibiotic resistance can be twofold. On one hand, it can limit the acquisition and dissemination of resistance genes through HGT. By cleaving the foreign plasmids or DNA that carry these resistance genes, CRISPR-Cas systems can act as a barrier to the spread of resistance within microbial populations [<xref ref-type="bibr" rid="CR72">72</xref>]. This has been demonstrated in studies where bacteria with active CRISPR systems were less likely to acquire plasmids carrying ARGs compared to CRISPR-deficient strains [<xref ref-type="bibr" rid="CR82">82</xref>]. On the other hand, some studies suggest that bacteria may develop resistance to the CRISPR-Cas system itself, allowing the persistence of antibiotic resistance. For example, mutations in the CRISPR sequences or the Cas proteins can result in the loss of immune function, facilitating the accumulation and spread of resistance genes. In some cases, bacteria have developed mechanisms to suppress CRISPR activity or acquire immunity to specific Cas proteins, which could allow the persistence of resistance genes even in the presence of CRISPR-mediated defense [<xref ref-type="bibr" rid="CR83">83</xref>]. Moreover, CRISPR-Cas systems have been shown to influence the evolution of multidrug resistance in clinical isolates, where CRISPR interference could contribute to the selection of resistant strains by altering the bacterial genomic landscape [<xref ref-type="bibr" rid="CR84">84</xref>]. CRISPR interference with mobile genetic elements carrying ARGs may also be influenced by bacterial population dynamics. In densely populated communities, the horizontal transfer of resistance genes can be a key factor in the spread of resistance. The CRISPR-Cas system's role in limiting or enhancing this transfer is context-dependent, varying based on the strain, environmental factors, and the specific type of CRISPR system present. For instance, Type I and Type III CRISPR systems, which primarily target RNA and DNA, may exert different selective pressures on the spread of resistance compared to the more widely studied Type II system, which is used in genome editing [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. Furthermore, the relationship between CRISPR-Cas systems and antibiotic resistance is not always direct. Other factors, such as the presence of specific bacteriophages or the dynamics of microbial communities, can modify the impact of CRISPR on antibiotic resistance. For example, phage therapy has been proposed as an alternative to antibiotics, where the CRISPR-Cas system could prevent bacterial adaptation to phages, but it may also interfere with the phage&#x02019;s ability to deliver genetic material, including resistance traits, to bacterial hosts [<xref ref-type="bibr" rid="CR86">86</xref>].</p></sec><sec id="Sec14"><title>Applications of nanoparticles in antibiotic therapy</title><p id="Par31">Nanoparticles (NPs) are increasingly explored for their potential in enhancing antibiotic therapy, primarily due to their unique physicochemical properties, such as high surface area, size-dependent behavior, and the ability to modify surface interactions. These features enable nanoparticles to overcome the challenges posed by conventional antibiotics, such as poor bioavailability, rapid clearance, and the emergence of antibiotic-resistant bacteria. The ability of nanoparticles to deliver drugs more effectively, enhance their stability, and offer targeted therapy has made them a promising tool in combating antibiotic-resistant infections [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. Nanoparticles, especially liposomes, micelles, dendrimers, and polymeric NPs, have shown promising applications as carriers for antibiotics. The high surface-to-volume ratio of NPs facilitates the encapsulation of hydrophobic antibiotics, thereby improving their solubility, stability, and bioavailability. Furthermore, targeted drug delivery is achieved by functionalizing NPs with ligands that selectively bind to bacterial cells, ensuring enhanced local concentrations of antibiotics at the site of infection [<xref ref-type="bibr" rid="CR89">89</xref>].</p></sec><sec id="Sec15"><title>Drug/gene delivery to combat bacterial infection</title><p id="Par32">The mechanism of action of drug and gene delivery systems is essential to understand in order to optimize the therapeutic efficacy against bacterial infections. The fundamental goal of both drug and gene delivery is to selectively target bacterial cells or infected tissues, allowing for the efficient release of therapeutic agents at the site of infection while minimizing systemic toxicity. Several mechanisms are employed in the delivery of drugs and genes to combat bacterial infections, with the most prominent ones being passive targeting, active targeting, and stimuli-responsive release [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR91">91</xref>].</p></sec><sec id="Sec16"><title>Drug delivery mechanisms</title><sec id="Sec17"><title>Passive targeting</title><p id="Par33">Passive targeting relies on the physicochemical properties of the drug delivery system and the biological environment. One of the most common strategies for passive targeting is the use of nanoparticles, which are designed to exploit the enhanced permeability and retention (EPR) effect. The EPR effect occurs in the inflamed or infected tissues, where blood vessels become leaky, allowing nanoparticles to accumulate at higher concentrations. This mechanism is particularly useful for delivering antibiotics to sites of infection, such as abscesses or chronic wounds [<xref ref-type="bibr" rid="CR92">92</xref>].</p></sec><sec id="Sec18"><title>Active targeting</title><p id="Par34">Active targeting involves the modification of the surface of drug carriers to enable recognition by specific bacterial cells or infected tissue. This can be achieved by functionalizing nanoparticles with ligands (such as antibodies, peptides, or aptamers) that bind to specific bacterial surface markers. For example, liposomes or polymeric nanoparticles can be conjugated with antibodies against bacterial antigens like lipopolysaccharides on Gram-negative bacteria, allowing for targeted delivery of antibiotics [<xref ref-type="bibr" rid="CR93">93</xref>]. Additionally, bacterial receptors such as pili or fimbriae can be exploited for targeting bacterial cells directly [<xref ref-type="bibr" rid="CR92">92</xref>].</p></sec><sec id="Sec19"><title>Controlled release and nanocarriers</title><p id="Par35">Nanocarriers, such as liposomes, micelles, and dendrimers, can encapsulate drugs and control their release at the site of infection. These carriers often employ diffusion, degradation, or swelling mechanisms to release the drug over time. For example, a pH-sensitive polymeric carrier will release its contents in an acidic environment, which is typical of infected tissues. Additionally, some nanocarriers respond to the enzymatic activity in the bacterial cell wall or biofilms, ensuring that the antibiotic is released only when it reaches the targeted site [<xref ref-type="bibr" rid="CR92">92</xref>].</p></sec></sec><sec id="Sec20"><title>Gene delivery mechanisms</title><sec id="Sec21"><title>Plasmid DNA delivery</title><p id="Par36">One of the most straightforward gene delivery mechanisms involves the use of plasmid DNA, which is delivered directly into bacterial cells or host tissues to express antimicrobial peptides, enzymes, or other therapeutic proteins. This is typically achieved using viral vectors, such as adenoviruses or lentiviruses, which can deliver genes into the target cells. Alternatively, non-viral vectors such as cationic liposomes or nanoparticles can facilitate the uptake of plasmid DNA through endocytosis [<xref ref-type="bibr" rid="CR94">94</xref>]. Upon internalization, the plasmid DNA is released into the cytoplasm, where it can be transcribed and translated into the desired therapeutic proteins [<xref ref-type="bibr" rid="CR95">95</xref>].</p></sec><sec id="Sec22"><title>CRISPR-Cas9 gene editing</title><p id="Par37">Delivery of CRISPR-Cas9 components, such as the Cas9 protein and guide RNA, is achieved using nanoparticles or viral vectors. These systems allow for precise and targeted gene editing, which can either knock out bacterial resistance genes or enhance the host immune response against the infection [<xref ref-type="bibr" rid="CR96">96</xref>].</p></sec><sec id="Sec23"><title>Bacteriophage-based gene delivery</title><p id="Par38">In this approach, phages can be modified to deliver therapeutic genes directly to bacterial cells. The mechanism of action involves the bacteriophage attaching to specific receptors on bacterial cell walls, injecting its genetic material into the bacterium, and replicating inside the cell. This method can be used to deliver genes encoding antimicrobial peptides or enzymes that degrade bacterial cell walls, thus helping to combat infection. Furthermore, bacteriophage-derived systems can be used to disrupt bacterial biofilms, a common mechanism of antibiotic resistance [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR77">77</xref>].</p></sec><sec id="Sec24"><title>Stimuli-responsive gene delivery</title><p id="Par39">Gene delivery can also be enhanced by incorporating stimuli-responsive carriers. These carriers respond to environmental changes, such as pH, temperature, or specific enzymes found in the infection site, which trigger the release of therapeutic genes. For example, pH-sensitive nanoparticles can release their cargo when exposed to the acidic conditions present in infected tissues, ensuring that the gene therapy is localized to the site of infection [<xref ref-type="bibr" rid="CR97">97</xref>]. Such controlled release mechanisms are critical for minimizing side effects and improving therapeutic outcomes. Both drug and gene delivery mechanisms aim to improve the precision, efficacy, and safety of therapies used to combat bacterial infections. While drug delivery systems primarily focus on enhancing drug stability, bioavailability, and targeted delivery, gene delivery systems are focused on enhancing the host&#x02019;s defense mechanisms or directly disrupting bacterial virulence. The integration of nanoparticles, CRISPR technologies, and bacteriophage-based systems holds great promise in overcoming the challenges posed by antibiotic resistance and improving the overall management of bacterial infections [<xref ref-type="bibr" rid="CR55">55</xref>].</p></sec></sec><sec id="Sec25"><title>Enhancing antibiotic efficacy and overcoming resistance</title><p id="Par40">NPs can enhance the efficacy of antibiotics, particularly against multidrug-resistant (MDR) pathogens. They act as potent adjuvants, increasing bacterial membrane permeability and facilitating the uptake of antibiotics. Some NPs can also disrupt biofilms, a common feature of chronic infections caused by antibiotic-resistant bacteria. Metal-based NPs, such as silver (Ag NPs), gold (Au NPs), and copper oxide (CuO NPs), possess intrinsic antimicrobial properties, which, when combined with antibiotics, exhibit synergistic effects that can overcome resistance mechanisms [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. Beyond their role in drug delivery, some nanoparticles possess direct antibacterial properties. Metal and metal oxide nanoparticles interact with bacterial cells through mechanisms such as reactive oxygen species (ROS) generation, disruption of bacterial cell walls, and interference with cellular components like proteins and DNA. For instance, silver nanoparticles (Ag NPs) are known to release silver ions that damage bacterial cell membranes, leading to cell death. Similarly, copper oxide nanoparticles (CuO NPs) are effective against both Gram-positive and Gram-negative bacteria due to their ability to generate oxidative stress [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. One of the major challenges with conventional antibiotics is their systemic toxicity and side effects. NPs help reduce these effects by providing localized drug release, which limits the exposure of non-target tissues to high drug concentrations. Additionally [<xref ref-type="bibr" rid="CR102">102</xref>] or targeting moieties can further minimize toxicity while enhancing therapeutic outcomes. The integration of nanoparticles with antibiotics in combination therapies has proven to be a powerful strategy. Multifunctional nanoparticles can simultaneously deliver antibiotics and other therapeutic agents, such as anti-inflammatory or anticancer drugs, for a more comprehensive treatment approach. These NPs can also be engineered to respond to external stimuli like pH, temperature, or light, allowing for controlled and site-specific drug release [<xref ref-type="bibr" rid="CR103">103</xref>]. Despite the promising applications of nanoparticles in antibiotic therapy, several challenges remain. Issues such as potential toxicity, immune system interactions, and the large-scale production of nanoparticles need to be addressed. Furthermore, the long-term effects of NPs, particularly in terms of environmental and human health, require thorough investigation. Continued advancements in nanomaterial design, biocompatibility, and regulatory approval are essential for the clinical translation of nanoparticle-based antibiotic therapies [<xref ref-type="bibr" rid="CR104">104</xref>].</p></sec><sec id="Sec26"><title>Nanoparticles: carrier of the CRISPR-Cas system</title><p id="Par41">Traditional antimicrobial strategies often fail against biofilms, necessitating alternative approaches. CRISPR-Cas9, a genome-editing tool capable of precise genetic modifications, has emerged as a promising strategy for targeting biofilm-associated resistance genes. However, efficient delivery of CRISPR components into biofilms remains a major hurdle. Nanoparticle-based delivery systems offer a viable solution by enhancing CRISPR-Cas9 stability, biofilm penetration, and targeted bacterial eradication [<xref ref-type="bibr" rid="CR9">9</xref>]. Nanoparticles have emerged as promising carriers for the CRISPR-Cas system, addressing the challenges of efficient gene editing by improving the delivery of CRISPR components to target cells, tissues, or organs [<xref ref-type="bibr" rid="CR96">96</xref>]. The CRISPR-Cas system, especially the CRISPR-Cas9 gene-editing tool, requires efficient delivery to ensure successful genetic modification (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Nanoparticles, due to their unique physical and chemical properties such as high surface-area-to-volume ratio and ability to encapsulate both hydrophilic and hydrophobic substances, provide an effective solution [<xref ref-type="bibr" rid="CR7">7</xref>]. Different types of nanoparticles have been explored for CRISPR delivery (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Liposomes, lipid-based nanoparticles, are among the most commonly used because of their ability to fuse with cell membranes, facilitating the transport of CRISPR components such as Cas9 proteins and guide RNAs (gRNAs) [<xref ref-type="bibr" rid="CR105">105</xref>]. Polymeric nanoparticles, created from synthetic or natural polymers, have also shown promise due to their capacity to package CRISPR components and control release, protecting the system from degradation [<xref ref-type="bibr" rid="CR6">6</xref>]. Inorganic nanoparticles, including gold, silica, and iron oxide nanoparticles, offer additional benefits due to their stability and ability to be functionalized for gene delivery or imaging purposes. Exosome-mimetic nanoparticles, which are modeled after naturally occurring exosomes, also present a unique approach to delivering CRISPR systems, capitalizing on their inherent ability to interact with cells [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. The mechanisms of nanoparticle-mediated CRISPR-Cas delivery involve the uptake of nanoparticles through cellular pathways such as endocytosis, which can occur via clathrin-mediated or caveolin-mediated routes. Once inside the cell, the nanoparticles must release the CRISPR components into the cytoplasm, often overcoming barriers such as the endosomal membrane. Once the Cas9 protein reaches the nucleus, it induces double-strand breaks in the target DNA, leading to gene knockout or insertion via the cell's DNA repair machinery [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. Various nanoparticles (NPs) have been designed to enhance CRISPR-Cas9 delivery for biofilm eradication. Lipid nanoparticles (LNPs) provide high transfection efficiency and protect CRISPR components from enzymatic degradation. Polymeric nanoparticles, such as poly (lactic-co-glycolic acid) (PLGA) and chitosan-based NPs, offer controlled release and biofilm-targeting capabilities. Inorganic nanoparticles, including gold and silica-based NPs, enhance stability and can be functionalized for specific targeting. Additionally, cell-penetrating peptide-modified NPs facilitate uptake by bacterial cells and biofilm penetration [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. While CRISPR-Cas9 systems are often scrutinized for their off-target gene-editing effects, the nanoparticle carriers themselves introduce additional risks related to delivery specificity. In particular, cationic nanoparticles, which are frequently employed for complexing negatively charged nucleic acids, exhibit a high affinity for anionic host cell membranes. This property can result in nonspecific cellular uptake, leading to off-target delivery in mammalian cells and reduced therapeutic precision [<xref ref-type="bibr" rid="CR109">109</xref>]. Surface modifications, such as PEGylation or zwitterionic coatings, have been shown to reduce unintended interactions and improve biocompatibility, but optimization must be tailored to the specific delivery context [<xref ref-type="bibr" rid="CR110">110</xref>]. However, the nanoparticle-mediated CRISPR delivery systems have several challenges. Toxicity is a concern, as some nanoparticles can damage cells or organs. Furthermore, not all cells take up nanoparticles efficiently, which can hinder the overall delivery efficacy. Despite advances, off-target gene editing remains a problem for CRISPR/Cas9 system, although improved targeting strategies with nanoparticles are being explored to enhance precision. Additionally, immune responses against synthetic nanoparticles can limit their therapeutic potential [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]. Another critical consideration is the bioaccumulation potential of inorganic nanoparticles, particularly metal-based carriers such as gold (AuNPs) or silver nanoparticles (AgNPs). These particles, while effective in enhancing CRISPR delivery and biofilm penetration, are known to accumulate in the liver, spleen, and other reticuloendothelial tissues, potentially triggering long-term toxicity or immune responses [<xref ref-type="bibr" rid="CR111">111</xref>]. Chronic exposure studies in animal models have shown that even low-dose accumulation of metal nanoparticles may alter hepatic function and induce oxidative stress [<xref ref-type="bibr" rid="CR112">112</xref>]. Thus, comprehensive in vivo biosafety assessments are essential before clinical translation of nanoparticle-assisted CRISPR therapeutics. Recent developments focus on optimizing the size, charge, and surface functionalization of nanoparticles to improve CRISPR delivery [<xref ref-type="bibr" rid="CR96">96</xref>]. Surface functionalization, using targeting ligands such as antibodies or peptides, helps guide nanoparticles to specific cell types and reduces unintended interactions. Moreover, stimuli-responsive nanoparticles that respond to environmental cues such as pH or temperature offer controlled release of CRISPR components at the desired target site [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. The efficacy of CRISPR&#x02013;nanoparticle systems in treating biofilm-associated infections depends not only on the engineering of advanced nanocarriers but also on a nuanced understanding of the microbiological microenvironment. Mature biofilms exhibit localized acidic conditions (pH 5.0&#x02013;6.5) due to anaerobic bacterial metabolism, which provides a unique physicochemical cue for targeted drug release. pH-responsive nanoparticles, typically constructed from acid-labile linkers or protonatable polymers (e.g., poly(histidine), poly(&#x003b2;-amino esters)), are designed to remain stable at physiological pH but undergo destabilization or payload release in acidic niches [<xref ref-type="bibr" rid="CR113">113</xref>]. This allows CRISPR-Cas cargos to be released precisely within the biofilm matrix, minimizing premature degradation and maximizing localized gene editing. For example, Tu et al. (2020) demonstrated that acid-sensitive polymeric nanoparticles could effectively release CRISPR/Cas9 payloads in acidic tumor microenvironments, a strategy directly translatable to acidic biofilm cores [<xref ref-type="bibr" rid="CR114">114</xref>]. Such interdisciplinary integration of material science and microbiological insight is essential for achieving spatially controlled delivery and enhancing therapeutic specificity. The synergistic effect between CRISPR/Cas9 and nanoparticle carriers arises from the complementary strengths of both systems, particularly in overcoming biofilm-associated delivery barriers. Cationic or surface-functionalized nanoparticles can disrupt the extracellular polymeric substance (EPS) matrix through electrostatic interaction or enzymatic co-loading, thereby improving the penetration of CRISPR components into deeper biofilm layers [<xref ref-type="bibr" rid="CR115">115</xref>]. Additionally, ligand-modified nanoparticles, such as those functionalized with bacterium-specific antibodies or antimicrobial peptides, enhance targeting specificity, reducing off-target effects and increasing CRISPR localization at infection sites [<xref ref-type="bibr" rid="CR114">114</xref>]. Moreover, pH-responsive or redox-responsive nanocarriers are designed to release CRISPR cargos selectively within acidic or oxidative microenvironments typical of mature biofilms, ensuring spatially controlled gene editing [<xref ref-type="bibr" rid="CR113">113</xref>]. In some designs, nanoparticles act as co-delivery platforms, carrying both CRISPR constructs and traditional antibiotics or EPS-degrading enzymes, achieving a multi-pronged disruption of biofilm defenses and promoting synergistic bacterial clearance [<xref ref-type="bibr" rid="CR116">116</xref>]. Nanoparticle-mediated CRISPR-Cas delivery has broad applications. Gene therapy has the potential to treat genetic disorders by enabling precise genetic modifications in somatic cells. In cancer therapy, CRISPR-Cas9 can be used to modify immune cells, such as T cells, to enhance their ability to target cancer cells. Furthermore, agricultural biotechnology benefits from CRISPR technology for crop modification, with nanoparticles improving the delivery of CRISPR systems into plant cells to generate traits such as disease resistance or increased yield [<xref ref-type="bibr" rid="CR107">107</xref>]. Recent studies have emphasized the need for safer, more efficient nanoparticle formulations. Innovations in nanoparticle design, including biocompatible materials, targeted delivery, and responsive systems, are paving the way for the broader application of CRISPR-Cas9 in clinical and agricultural settings [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>].
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Integrated classification and comparative analysis of CRISPR-Cas system subtypes with respect to antimicrobial mechanisms, nanoparticle delivery compatibility, and translational potential</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Class</th><th align="left">Type</th><th align="left">Sub-type</th><th align="left">Description</th><th align="left">Target</th><th align="left">Effector</th><th align="left">CRISPR Protein</th><th align="left">PAM/PFS</th><th align="left">Associated type-subtype</th><th align="left">Function</th><th align="left">Mechanism of antimicrobial action</th><th align="left">NP delivery compatibility</th><th align="left">Translational readiness</th><th align="left">Ethical/regulatory note</th><th align="left">Application potential</th><th align="left">Ref</th></tr></thead><tbody><tr><td align="left" rowspan="19">Class 1</td><td align="left" rowspan="10">Type I</td><td align="left">A</td><td align="left" rowspan="10">Multi-subunit crRNA-effector complex</td><td align="left" rowspan="10">dsDNA</td><td align="left">Cascade</td><td align="left"><p>Cas 1</p><p><bold>Cas 3</bold></p><p>Cas 6</p></td><td align="left" rowspan="19">-</td><td align="left" rowspan="10">I, II, III-A, III-B, IV, possibly VI</td><td align="left" rowspan="10">DNA Nuclease and helicase activity</td><td align="left" rowspan="10">Cas3 degrades DNA unidirectionally after Cascade complex binding; enables"genome shredding"of resistance plasmids</td><td align="left" rowspan="10">Limited due to large complex size (multi-protein); needs innovative nano-encapsulation</td><td align="left" rowspan="10">In vitro efficacy confirmed; no in vivo or clinical delivery reported</td><td align="left" rowspan="10">DNA destruction is irreversible; biosecurity and containment are concerns</td><td align="left" rowspan="10">Multi-subunit system for processive DNA degradation. Experimentally explored to remove resistance plasmids and disrupt essential bacterial genes in persistent infections. Potential use in anti-biofilm strategies via genome shredding</td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>&#x02013;<xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td align="left">B</td><td align="left">Cascade</td><td align="left"><p>Cas 1</p><p><bold>Cas 3</bold></p><p>Cas 6</p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>&#x02013;<xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td align="left">C</td><td align="left">Cascade</td><td align="left"><p>Cas 1</p><p><bold>Cas 3</bold></p><p>Cas 5</p><p>Cas 6</p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>&#x02013;<xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td align="left">C variant</td><td align="left">Cascade</td><td align="left"><p>Cas 5</p><p>Cas 6</p><p><bold>Cas3</bold></p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>&#x02013;<xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td align="left">D</td><td align="left">Hybrid features of Type I and III</td><td align="left"><p>Cas 1</p><p>Cas 6</p><p><bold>Cas 3</bold></p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR121">121</xref>&#x02013;<xref ref-type="bibr" rid="CR123">123</xref>]</td></tr><tr><td align="left">E</td><td align="left">Cascade</td><td align="left"><p>Cas 1</p><p><bold>Cas 3</bold></p><p>Cas 6</p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]</td></tr><tr><td align="left">F</td><td align="left">Csy-complex</td><td align="left"><p>Cas 1</p><p><bold>Cas 3</bold></p><p>Cas 6</p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td align="left">F variant 1</td><td align="left">Csy-complex</td><td align="left"><p>Cas 1</p><p><bold>Cas 3</bold></p><p>Cas 6</p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td align="left">F variant 2</td><td align="left">Csy-complex</td><td align="left"><p>Cas 1</p><p><bold>Cas 3</bold></p><p>Cas 6</p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td align="left">U</td><td align="left">Cascade</td><td align="left"><p>Cas 1</p><p><bold>Cas 3</bold></p><p>Cas 6</p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td align="left" rowspan="6">Type III</td><td align="left">A</td><td align="left" rowspan="6">Multi-subunit crRNA-effector complex</td><td align="left" rowspan="6">ssRNA</td><td align="left">Csm complex</td><td align="left"><p>Cas 2</p><p>Cas 6</p><p>Cas 8</p><p><bold>Cas 10</bold></p></td><td align="left" rowspan="6">I, II, III-A, III-B, V, some VI</td><td align="left" rowspan="6"><p>RNA Nuclease</p><p>(Cleaving)</p></td><td align="left" rowspan="6">Dual targeting of DNA and RNA; suitable for adaptive multi-pathway suppression of resistance and virulence</td><td align="left" rowspan="6">Complex structure limits delivery; still not validated in NP systems</td><td align="left" rowspan="6">Experimental phase; theoretical antimicrobial utility</td><td align="left" rowspan="6">Dual-action raises complexity in predicting off-targets and safety</td><td align="left" rowspan="6">Dual-action targeting of DNA and RNA makes it promising for managing complex infections involving horizontal gene transfer or mobile elements. May be valuable for real-time bacterial control but requires further optimization for nanocarrier compatibility</td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]</td></tr><tr><td align="left">A variant</td><td align="left">Csm complex</td><td align="left"><p>Cas 2</p><p>Cas 6</p><p>Cas 8</p><p><bold>Cas 10</bold></p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]</td></tr><tr><td align="left">B</td><td align="left">Cmr complex</td><td align="left"><p>Cas 2</p><p>Cas 6</p><p>Cas 8</p><p><bold>Cas 10</bold></p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]</td></tr><tr><td align="left">B variant</td><td align="left">Cascade</td><td align="left"><p>Cas 2</p><p>Cas 6</p><p>Cas 8</p><p><bold>Cas 10</bold></p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]</td></tr><tr><td align="left">C</td><td align="left">Cascade</td><td align="left"><p>Cas 2</p><p>Cas 6</p><p>Cas 8</p><p><bold>Cas 10</bold></p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]</td></tr><tr><td align="left">D</td><td align="left">Cascade</td><td align="left"><p>Cas 2</p><p>Cas 6</p><p>Cas 8</p><p><bold>Cas 10</bold></p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]</td></tr><tr><td align="left" rowspan="3">Type IV</td><td align="left">A</td><td align="left" rowspan="3">Multi-subunit crRNA-effector complex</td><td align="left" rowspan="3">dsDNA</td><td align="left">Cascade</td><td align="left"><p>Cas 3</p><p><bold>Csf1</bold>(Cas8)</p></td><td align="left" rowspan="3">I</td><td align="left" rowspan="3">Unknown/putative interference role (under investigation)</td><td align="left" rowspan="3">Suspected to restrict plasmid transfer and horizontal gene resistance spread</td><td align="left" rowspan="3">Not studied yet; lack of effector characterization limits formulation</td><td align="left" rowspan="3">Conceptual only; no in vitro or in vivo validations</td><td align="left" rowspan="3">No known risks; field underexplored</td><td align="left" rowspan="3">Poorly characterized; possibly involved in plasmid interference and restriction of mobile genetic elements. Could be useful for removing resistance plasmids in the future. Clinical applications remain speculative due to lack of adaptation machinery</td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR127">127</xref>&#x02013;<xref ref-type="bibr" rid="CR130">130</xref>]</td></tr><tr><td align="left">A variant</td><td align="left">Cascade</td><td align="left"><p>Cas 3</p><p><bold>Csf1</bold>(Cas8)</p></td><td align="left"/></tr><tr><td align="left">B</td><td align="left">Cascade</td><td align="left"><bold>Csf1</bold>(Cas8)</td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR127">127</xref>&#x02013;<xref ref-type="bibr" rid="CR130">130</xref>]</td></tr><tr><td align="left" rowspan="12">Class 2</td><td align="left" rowspan="4">Type II</td><td align="left">A</td><td align="left" rowspan="4">Single-subunit crRNA-effector module (Cas9)</td><td align="left">dsDNA</td><td align="left">SpCas9</td><td align="left"><p>Cas 5</p><p><bold>Cas 9</bold></p></td><td align="left">NGG SpCas9</td><td align="left">Type I, I</td><td align="left"><p>Ribonuclease responsible for converting pre-crRNA to mature crRNA</p><p>(Cleaving)</p></td><td align="left" rowspan="4">Creates dsDNA breaks in resistance genes (e.g., <italic>mecA</italic>, <italic>blaNDM-1</italic>), blocking replication or plasmid stability</td><td align="left" rowspan="4">Highly compatible with lipid-based NPs, polymeric NPs, and exosomes. Cas9 protein or mRNA can be co-packaged with sgRNA</td><td align="left" rowspan="4">Currently in preclinical and early-phase human trials for antimicrobial and genetic diseases</td><td align="left" rowspan="4">Risk of off-target editing and immunogenicity. Regulatory guidelines under development for microbial gene-editing therapies</td><td align="left" rowspan="4">Precise DNA editing enables knockout of resistance genes (e.g., <italic>mecA</italic>, <italic>blaNDM-1</italic>) and disruption of biofilm-associated loci (e.g., <italic>icaA</italic>). Widely used in antimicrobial gene targeting and restoration of antibiotic susceptibility in drug-resistant bacteria. Compatible with diverse NP carriers for targeted delivery</td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR131">131</xref>&#x02013;<xref ref-type="bibr" rid="CR136">136</xref>]</td></tr><tr><td align="left">A variant</td><td align="left">dsDNA</td><td align="left">SaCas9</td><td align="left"><p>Cas 5</p><p><bold>Cas 9</bold></p></td><td align="left">NNGRRT SaCas9</td><td align="left">Type I, I</td><td align="left"><p>Ribonuclease responsible for converting pre-crRNA to mature crRNA</p><p>(Cleaving)</p></td><td align="left"> [<xref ref-type="bibr" rid="CR131">131</xref>&#x02013;<xref ref-type="bibr" rid="CR136">136</xref>]</td></tr><tr><td align="left">B</td><td align="left">dsDNA/ssRNA</td><td align="left">FnCas9</td><td align="left"><p>Cas 6</p><p><bold>Cas 9</bold></p></td><td align="left">NGG FnCas9</td><td align="left">Most type IIIB and type I</td><td align="left"><p>Pre-crRNA is converted to mature crRNA by ribonuclease</p><p>(Cleaving)</p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR131">131</xref>&#x02013;<xref ref-type="bibr" rid="CR135">135</xref>]</td></tr><tr><td align="left">C</td><td align="left">dsDNA</td><td align="left">NmCas9</td><td align="left"><p>Cas 7</p><p><bold>Cas 9</bold></p></td><td align="left">NNNNGATT NmCas9</td><td align="left">I, III, IV</td><td align="left"><p>It binds with crRNA and comprises of an RNA recognition motif</p><p>(Cleaving)</p></td><td align="left"> [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR132">132</xref>&#x02013;<xref ref-type="bibr" rid="CR135">135</xref>]</td></tr><tr><td align="left" rowspan="3">Type V</td><td align="left">A</td><td align="left" rowspan="3">Single-subunit crRNA-effector module (Cas12)</td><td align="left" rowspan="3">dsDNA</td><td align="left"><p>Cas12a (Cpf1)</p><p>RuvC&#x02009;+&#x02009;Nuc domain</p></td><td align="left"><p>Cas 8</p><p>Cas 12</p><p>Cpf1</p></td><td align="left">50 AT-rich PAM TTTV</td><td align="left">Most type I</td><td align="left"><p>It forms effector complex large subunit in type I</p><p>(Cleaving with cpf1)</p></td><td align="left" rowspan="3">Cuts target DNA and triggers collateral ssDNA cleavage, enabling broader bacterial genome targeting and biofilm matrix degradation</td><td align="left" rowspan="3">Small size and self-processing capability make it ideal for lipid and polymeric NP encapsulation</td><td align="left" rowspan="3">Used in diagnostics (DETECTR), preclinical therapeutic designs underway</td><td align="left" rowspan="3">Lower immunogenicity; collateral activity may affect safety. Monitoring required in clinical translation</td><td align="left" rowspan="3">Offers gene editing with collateral cleavage potential, allowing both gene disruption and DNA degradation. Its self-processing ability simplifies NP delivery design. Applied in biofilm removal, bacterial genome disruption, and CRISPR-based diagnostics</td><td align="left"> [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR137">137</xref>&#x02013;<xref ref-type="bibr" rid="CR142">142</xref>]</td></tr><tr><td align="left">B</td><td align="left"><p>Cas12b (C2c1)</p><p>RuvC</p></td><td align="left"><p>Cas 9</p><p>Cas 12</p><p>Cpf1</p></td><td align="left">50 AT-rich PAM TTTV</td><td align="left">II only</td><td align="left"><p>DNA nuclease</p><p>(Cleaving with cpf1)</p></td><td align="left"> [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR137">137</xref>&#x02013;<xref ref-type="bibr" rid="CR143">143</xref>]</td></tr><tr><td align="left">C</td><td align="left"><p>Cas12c (C2c3)</p><p>RuvC</p></td><td align="left"><p>Cas 10</p><p>Cas 12</p><p>Cpf1</p></td><td align="left">50 AT-rich PAM TTTV</td><td align="left">Some type I, most type III</td><td align="left"><p>It forms effector complex large subunit in type III</p><p>(Cleaving with cpf1)</p></td><td align="left"> [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR137">137</xref>&#x02013;<xref ref-type="bibr" rid="CR143">143</xref>]</td></tr><tr><td align="left" rowspan="5">Type VI</td><td align="left">A</td><td align="left" rowspan="5">Single-subunit crRNA-effector module (Cas13)</td><td align="left" rowspan="5">ssRNA</td><td align="left">Cas13a (C2c2)</td><td align="left"><p>Cas 12 (cpf1)</p><p>Cas 13</p></td><td align="left"><p>30</p><p>PFS: non-G</p></td><td align="left">V</td><td align="left">crRNA sorting, DNA nuclease</td><td align="left" rowspan="5">Degrades target RNA (e.g., resistance or virulence mRNAs), blocking protein synthesis; collateral RNA degradation in pathogens</td><td align="left" rowspan="5">Ideal for transient therapies; loaded as RNP or mRNA into lipid/polymer/hydrogel NPs</td><td align="left" rowspan="5">SHERLOCK-based diagnostics approved under EUA by FDA; therapeutic uses under study</td><td align="left" rowspan="5">Considered safer than Cas9 due to RNA-only targeting; potential for off-pathway RNA collateral cleavage</td><td align="left" rowspan="5">Targets bacterial or viral RNA, allowing suppression of gene expression without altering DNA. Promising for transient gene control in pathogens and CRISPR-based antimicrobials or diagnostics (e.g., SHERLOCK). Suitable for resistant infections involving RNA regulation</td><td align="left"> [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR144">144</xref>&#x02013;<xref ref-type="bibr" rid="CR149">149</xref>]</td></tr><tr><td align="left">B-1</td><td align="left">Cas13b (C2c4)</td><td align="left">Cas 13 (C2c2)</td><td align="left"><p>50</p><p>PFS: non-C; 30</p><p>PFS:NAN/NNA</p></td><td align="left">VI</td><td align="left">crRNA sorting, RNA nuclease</td><td align="left"> [<xref ref-type="bibr" rid="CR145">145</xref>&#x02013;<xref ref-type="bibr" rid="CR151">151</xref>]</td></tr><tr><td align="left">B-2</td><td align="left">Cas13b (C2c4)</td><td align="left">Cas 13 (C2c2)</td><td align="left"><p>50</p><p>PFS: non-C; 30</p><p>PFS:NAN/NNA</p></td><td align="left"/><td align="left">crRNA sorting, RNA nuclease</td><td align="left"> [<xref ref-type="bibr" rid="CR146">146</xref>&#x02013;<xref ref-type="bibr" rid="CR151">151</xref>]</td></tr><tr><td align="left">C</td><td align="left">Cas13c (C2c7)</td><td align="left"><p>Csm, Cmr</p><p>Cas 13</p></td><td align="left">-</td><td align="left">III</td><td align="left">Nucleases for single-stranded DNA and RNA</td><td align="left"> [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR146">146</xref>&#x02013;<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]</td></tr><tr><td align="left">D</td><td align="left">Cas13d</td><td align="left"><p>RNase III</p><p>Cas 13</p></td><td align="left">-</td><td align="left">II</td><td align="left">tracrRNA is processed, and crRNA maturation is aided by this system</td><td align="left"> [<xref ref-type="bibr" rid="CR146">146</xref>&#x02013;<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR154">154</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec27"><title>Future directions and challenges</title><p id="Par42">Despite its potential, CRISPR-based anti-biofilm strategies face several hurdles. The delivery of CRISPR components into biofilm-embedded bacteria remains a major challenge, necessitating the use of bacteriophages, nanoparticles, or electroporation techniques. Moreover, the risk of off-target effects and bacterial evolution against CRISPR-based attacks requires further investigation. Nevertheless, the development of CRISPR-Cas antimicrobials represents a promising frontier in tackling biofilm-associated bacterial resistance, with potential applications in clinical and industrial settings [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. The application of CRISPR/Cas9 in biofilm control presents several anticipated opportunities, novel hypotheses, and inherent challenges, particularly when focusing on molecular mechanisms and biofilm-related genes. CRISPR/Cas9 allows sequence-specific targeting of genes essential for biofilm formation, maintenance, and dispersal. One of the major strategies involves disrupting quorum sensing (QS) pathways, which regulate biofilm development [<xref ref-type="bibr" rid="CR155">155</xref>]. The <italic>lasR</italic> and <italic>rhlR</italic> genes in <italic>Pseudomonas aeruginosa</italic>, encoding transcriptional regulators of QS, are prime targets for CRISPR/Cas9-mediated disruption, effectively reducing biofilm formation [<xref ref-type="bibr" rid="CR156">156</xref>]. Similarly, targeting <italic>icaA</italic>, a critical gene in polysaccharide intercellular adhesin (PIA) synthesis in <italic>Staphylococcus aureus</italic>, significantly weakens biofilm integrity [<xref ref-type="bibr" rid="CR39">39</xref>]. Another promising approach is the utilization of CRISPR/Cas9-based antimicrobials to selectively eliminate antibiotic-resistant bacteria within biofilms. By designing guide RNAs (gRNAs) to target antibiotic resistance genes such as <italic>bla</italic>, <italic>mecA</italic>, and <italic>ndm-1</italic>, researchers have successfully sensitized biofilm-associated bacteria to conventional antibiotics. Furthermore, biofilm dispersal can be promoted by targeting regulators of cyclic-di-GMP signaling, such as <italic>pelA</italic> and <italic>bssR</italic>, which control biofilm stability in <italic>Escherichia coli</italic> and <italic>Pseudomonas aeruginosa</italic> [<xref ref-type="bibr" rid="CR157">157</xref>]. One major hurdle is the efficient delivery of CRISPR components into biofilm-embedded bacteria. The dense EPS matrix acts as a barrier, reducing the penetration of CRISPR/Cas9 systems delivered via plasmids, liposomes, or nanoparticles. Bacteriophage-mediated delivery shows potential, yet phage-host specificity limits its broad applicability. Another challenge is the emergence of CRISPR resistance in bacterial populations. Bacteria may develop mutations in the protospacer adjacent motif (PAM) sequence, preventing Cas9 recognition. Additionally, some bacterial species possess anti-CRISPR proteins (Acrs) that inhibit Cas9 activity, reducing its effectiveness. Strategies to overcome this limitation include using CRISPR/Cas variations such as Cas12a or Cas13, which have distinct PAM requirements and broader targeting potential. Furthermore, the unintended ecological consequences of biofilm-targeting CRISPR approaches require careful consideration. Biofilms play essential roles in environmental and industrial settings, including wastewater treatment and bioremediation. Uncontrolled disruption of biofilms could negatively impact these beneficial processes [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR157">157</xref>]. Therefore, the development of inducible CRISPR systems, where biofilm targeting is activated only under specific conditions, is a potential solution [<xref ref-type="bibr" rid="CR108">108</xref>]. These resistance mechanisms may limit the long-term effectiveness of CRISPR-based biofilm therapies. To overcome these challenges, researchers are exploring alternative Cas9 variants, such as Cpf1 (also known as Cas12a), which recognize different PAM sequences and may bypass some of the resistance mechanisms. Moreover, concerns about off-target effects, where CRISPR/Cas9 inadvertently edits unintended genomic loci, must be carefully considered, particularly in clinical or environmental applications. Advances in high-fidelity Cas9 variants and improved gRNA design strategies are being pursued to minimize these risks. This approach allows for more precise regulation of gene expression, offering a reversible means of controlling biofilm formation without the risk of inducing permanent genetic changes [<xref ref-type="bibr" rid="CR158">158</xref>]. CRISPRi (CRISPR interference) has already been applied to modulate biofilm-related genes in <italic>Pseudomonas aeruginosa</italic>, providing a potential alternative to gene knockouts [<xref ref-type="bibr" rid="CR72">72</xref>]. The combination of CRISPR/Cas9 with synthetic biology tools, such as inducible gene circuits and biosensors, could further enhance the specificity and control of biofilm-targeting strategies. By engineering bacteria to respond to environmental cues or to self-regulate CRISPR activity, it may be possible to create dynamic systems that can selectively disrupt biofilms under specific conditions, reducing the risk of unwanted side effects [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR86">86</xref>].</p></sec><sec id="Sec28"><title>Conclusions</title><p id="Par43">Bacterial biofilms represent a major challenge in healthcare and industry due to their enhanced resistance to antibiotics. The biofilm structure, characterized by an extracellular polymeric substance (EPS) matrix, provides mechanical protection and restricts antibiotic penetration. Furthermore, the ultrastructural organization of biofilms contributes to their persistence, metabolic heterogeneity, and intercellular communication through quorum sensing. The resistance mechanisms of bacterial biofilms are multifaceted and collectively render conventional antibiotic therapies less effective, necessitating novel approaches to combat biofilm-associated infections. One promising avenue is the CRISPR-Cas system, a prokaryotic adaptive immune mechanism that can be repurposed for precision genome editing. Specifically, CRISPR-Cas9, a widely studied variant, functions by introducing targeted double-stranded DNA breaks, facilitating genetic modifications. In the context of bacterial biofilms and antibiotic resistance, the CRISPR-Cas system offers potential solutions by selectively targeting resistance genes, biofilm-regulating pathways, and virulence factors. However, several hypotheses and challenges must be addressed, such as efficient delivery methods, off-target effects, bacterial immune evasion, and regulatory considerations. The interplay between CRISPR-Cas systems and antibiotic resistance is complex, as some bacterial strains possess endogenous CRISPR elements that can mediate resistance gene uptake or restriction, further complicating therapeutic strategies. Nanotechnology presents an innovative tool to enhance antibiotic therapy. Nanoparticles (NPs) exhibit intrinsic antibacterial properties and serve as efficient carriers for antibiotics or gene-editing tools. They can improve drug solubility, bioavailability, and targeted delivery, reducing off-target toxicity and overcoming bacterial resistance mechanisms. Nanoparticles in CRISPR-Cas9 delivery are particularly promising, offering enhanced protection of CRISPR components, controlled release, and improved cellular uptake within biofilms. The integration of CRISPR-Cas9 and nanotechnology holds immense potential for eradicating biofilm-related infections, but several hurdles remain, including optimizing nanoparticle formulations, ensuring biocompatibility, and scaling up production for clinical applications. Future research should focus on refining CRISPR-nanoparticle hybrid systems, assessing their long-term effects, and developing regulatory frameworks for safe and effective deployment. Overall, a multidisciplinary approach combining molecular genetics, nanotechnology, and bioengineering is essential to overcome biofilm-associated antibiotic resistance and revolutionize bacterial infection treatments.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CRISPR</term><def><p id="Par3">Clustered Regularly Interspaced Short Palindromic Repeats</p></def></def-item><def-item><term>Cas9</term><def><p id="Par4">CRISPR-associated protein 9</p></def></def-item><def-item><term>NPs</term><def><p id="Par5">Nanoparticles</p></def></def-item><def-item><term>PAM</term><def><p id="Par6">Protospacer adjacent motif</p></def></def-item><def-item><term>gRNA</term><def><p id="Par7">Guide RNA</p></def></def-item><def-item><term>HDR</term><def><p id="Par8">Homology-directed repair</p></def></def-item><def-item><term>NHEJ</term><def><p id="Par9">Non-homologous end joining</p></def></def-item><def-item><term>EPS</term><def><p id="Par10">Extracellular polymeric substances</p></def></def-item><def-item><term>PLGA</term><def><p id="Par11">Poly (lactic-co-glycolic acid)</p></def></def-item><def-item><term>DNA</term><def><p id="Par12">Deoxyribonucleic acid</p></def></def-item><def-item><term>RNA</term><def><p id="Par13">Ribonucleic acid</p></def></def-item><def-item><term>gDNA</term><def><p id="Par14">Genomic DNA</p></def></def-item><def-item><term>qPCR</term><def><p id="Par15">Quantitative polymerase chain reaction</p></def></def-item><def-item><term>PCR</term><def><p id="Par16">Polymerase chain reaction</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank all our colleagues for their assistance. The facility for this study was provided by Research Deputy of Kashan University of Medical Sciences.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>MP, EK, ASN, AKH, HHK conducted the literature and drafted the manuscript. All authors reviewed the manuscript and made significant revisions and approved the final version of the manuscript draft.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>No financial support was received.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par44">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par45">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par46">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Flemming</surname><given-names>H-C</given-names></name><name><surname>Wingender</surname><given-names>J</given-names></name><name><surname>Szewzyk</surname><given-names>U</given-names></name><name><surname>Steinberg</surname><given-names>P</given-names></name><name><surname>Rice</surname><given-names>SA</given-names></name><name><surname>Kjelleberg</surname><given-names>S</given-names></name></person-group><article-title>Biofilms: an emergent form of bacterial life</article-title><source>Nat Rev Microbiol</source><year>2016</year><volume>14</volume><issue>9</issue><fpage>563</fpage><lpage>575</lpage><?supplied-pmid 27510863?><pub-id pub-id-type="pmid">27510863</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Flemming H-C, Wingender J, Szewzyk U, Steinberg P, Rice SA, Kjelleberg S. Biofilms: an emergent form of bacterial life. Nat Rev Microbiol. 2016;14(9):563&#x02013;75.<pub-id pub-id-type="pmid">27510863</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Zuberi</surname><given-names>A</given-names></name><name><surname>Ahmad</surname><given-names>N</given-names></name><name><surname>Ahmad</surname><given-names>H</given-names></name><name><surname>Saeed</surname><given-names>M</given-names></name><name><surname>Ahmad</surname><given-names>I</given-names></name></person-group><article-title>Beyond antibiotics: CRISPR/Cas9 triumph over biofilm-associated antibiotic resistance infections</article-title><source>Front Cell Infect Microbiol</source><year>2024</year><volume>14</volume><fpage>1408569</fpage><?supplied-pmid 39035353?><pub-id pub-id-type="pmid">39035353</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Zuberi A, Ahmad N, Ahmad H, Saeed M, Ahmad I. Beyond antibiotics: CRISPR/Cas9 triumph over biofilm-associated antibiotic resistance infections. Front Cell Infect Microbiol. 2024;14:1408569.<pub-id pub-id-type="pmid">39035353</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Ciofu</surname><given-names>O</given-names></name><name><surname>Tolker-Nielsen</surname><given-names>T</given-names></name></person-group><article-title>Tolerance and resistance of <italic>Pseudomonas aeruginosa</italic> biofilms to antimicrobial agents-how <italic>P. aeruginosa</italic> can escape antibiotics</article-title><source>Front Microbiol</source><year>2019</year><volume>10</volume><fpage>913</fpage><?supplied-pmid 31130925?><pub-id pub-id-type="pmid">31130925</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Ciofu O, Tolker-Nielsen T. Tolerance and resistance of <italic>Pseudomonas aeruginosa</italic> biofilms to antimicrobial agents-how <italic>P. aeruginosa</italic> can escape antibiotics. Front Microbiol. 2019;10:913.<pub-id pub-id-type="pmid">31130925</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Jinek</surname><given-names>M</given-names></name><name><surname>Chylinski</surname><given-names>K</given-names></name><name><surname>Fonfara</surname><given-names>I</given-names></name><name><surname>Hauer</surname><given-names>M</given-names></name><name><surname>Doudna</surname><given-names>JA</given-names></name><name><surname>Charpentier</surname><given-names>E</given-names></name></person-group><article-title>A programmable dual-RNA&#x02013;guided DNA endonuclease in adaptive bacterial immunity</article-title><source>Science</source><year>2012</year><volume>337</volume><issue>6096</issue><fpage>816</fpage><lpage>821</lpage><?supplied-pmid 22745249?><pub-id pub-id-type="pmid">22745249</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA&#x02013;guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816&#x02013;21.<pub-id pub-id-type="pmid">22745249</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Ekwebelem</surname><given-names>OC</given-names></name><name><surname>Aleke</surname><given-names>J</given-names></name><name><surname>Ofielu</surname><given-names>E</given-names></name><name><surname>Nnorom-Dike</surname><given-names>O</given-names></name></person-group><article-title>CRISPR-Cas9 system: a revolutionary tool in the fight against antimicrobial resistance: retracted</article-title><source>Infect Microbes Dis</source><year>2021</year><volume>3</volume><issue>2</issue><fpage>51</fpage><lpage>56</lpage></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Ekwebelem OC, Aleke J, Ofielu E, Nnorom-Dike O. CRISPR-Cas9 system: a revolutionary tool in the fight against antimicrobial resistance: retracted. Infect Microbes Dis. 2021;3(2):51&#x02013;6.</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>RB</given-names></name><name><surname>Stokes</surname><given-names>LD</given-names></name><name><surname>Kelly</surname><given-names>IB</given-names><suffix>3rd</suffix></name><name><surname>Henderson</surname><given-names>KM</given-names></name><name><surname>Vallecillo-Viejo</surname><given-names>IC</given-names></name><name><surname>Colazo</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Nonviral in vivo delivery of CRISPR-Cas9 using protein-agnostic, high-loading porous silicon and polymer nanoparticles</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><issue>17</issue><fpage>16412</fpage><lpage>16431</lpage><?supplied-pmid 37582231?><pub-id pub-id-type="pmid">37582231</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Fletcher RB, Stokes LD, Kelly IB 3rd, Henderson KM, Vallecillo-Viejo IC, Colazo JM, et al. Nonviral in vivo delivery of CRISPR-Cas9 using protein-agnostic, high-loading porous silicon and polymer nanoparticles. ACS Nano. 2023;17(17):16412&#x02013;31.<pub-id pub-id-type="pmid">37582231</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>F</given-names></name><name><surname>Draz</surname><given-names>MS</given-names></name><name><surname>Gu</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Ruan</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name></person-group><article-title>Novel strategy to combat antibiotic resistance: a sight into the combination of CRISPR/Cas9 and nanoparticles</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><issue>3</issue><fpage>352</fpage><?supplied-pmid 33800235?><pub-id pub-id-type="pmid">33800235</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Wan F, Draz MS, Gu M, Yu W, Ruan Z, Luo Q. Novel strategy to combat antibiotic resistance: a sight into the combination of CRISPR/Cas9 and nanoparticles. Pharmaceutics. 2021;13(3):352.<pub-id pub-id-type="pmid">33800235</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Zohra</surname><given-names>T</given-names></name><name><surname>Numan</surname><given-names>M</given-names></name><name><surname>Ikram</surname><given-names>A</given-names></name><name><surname>Salman</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>T</given-names></name><name><surname>Din</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cracking the challenge of antimicrobial drug resistance with CRISPR/Cas9, nanotechnology and other strategies in ESKAPE pathogens</article-title><source>Microorganisms</source><year>2021</year><volume>9</volume><issue>5</issue><fpage>954</fpage><?supplied-pmid 33946643?><pub-id pub-id-type="pmid">33946643</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Zohra T, Numan M, Ikram A, Salman M, Khan T, Din M, et al. Cracking the challenge of antimicrobial drug resistance with CRISPR/Cas9, nanotechnology and other strategies in ESKAPE pathogens. Microorganisms. 2021;9(5):954.<pub-id pub-id-type="pmid">33946643</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Hwang</surname><given-names>Y</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Jang</surname><given-names>H-K</given-names></name><name><surname>Kim</surname><given-names>H-O</given-names></name></person-group><article-title>Advances in nanoparticles as non-viral vectors for efficient delivery of CRISPR/Cas9</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><issue>9</issue><fpage>1197</fpage><?supplied-pmid 39339233?><pub-id pub-id-type="pmid">39339233</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Kim M, Hwang Y, Lim S, Jang H-K, Kim H-O. Advances in nanoparticles as non-viral vectors for efficient delivery of CRISPR/Cas9. Pharmaceutics. 2024;16(9):1197.<pub-id pub-id-type="pmid">39339233</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>K</given-names></name><name><surname>Slay</surname><given-names>B</given-names></name><name><surname>Knackstedt</surname><given-names>M</given-names></name><name><surname>Gaharwar</surname><given-names>AK</given-names></name></person-group><article-title>Antimicrobial activity of metal and metal-oxide based nanoparticles</article-title><source>Adv Ther</source><year>2018</year><volume>1</volume><issue>3</issue><fpage>1700033</fpage></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Gold K, Slay B, Knackstedt M, Gaharwar AK. Antimicrobial activity of metal and metal-oxide based nanoparticles. Adv Ther. 2018;1(3):1700033.</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Xin</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name></person-group><article-title>Construction of stable microbial consortia for effective biochemical synthesis</article-title><source>Trends Biotechnol</source><year>2023</year><volume>41</volume><issue>11</issue><fpage>1430</fpage><lpage>1441</lpage><?supplied-pmid 37330325?><pub-id pub-id-type="pmid">37330325</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Jiang Y, Wu R, Zhang W, Xin F, Jiang M. Construction of stable microbial consortia for effective biochemical synthesis. Trends Biotechnol. 2023;41(11):1430&#x02013;41.<pub-id pub-id-type="pmid">37330325</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>K</given-names></name><name><surname>Bradford</surname><given-names>PA</given-names></name></person-group><article-title>&#x003b2;-lactams and &#x003b2;-lactamase inhibitors: an overview</article-title><source>Cold Spring Harb Perspect Med</source><year>2016</year><volume>6</volume><issue>8</issue><fpage>a025247</fpage><?supplied-pmid 27329032?><pub-id pub-id-type="pmid">27329032</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Bush K, Bradford PA. &#x003b2;-lactams and &#x003b2;-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8):a025247.<pub-id pub-id-type="pmid">27329032</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>D</given-names></name></person-group><article-title>Origins and evolution of antibiotic resistance</article-title><source>Microbiol Mol Biol Rev</source><year>2010</year><volume>74</volume><issue>3</issue><fpage>417</fpage><lpage>433</lpage><?supplied-pmid 20805405?><pub-id pub-id-type="pmid">20805405</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417&#x02013;33.<pub-id pub-id-type="pmid">20805405</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X-Z</given-names></name><name><surname>Nikaido</surname><given-names>H</given-names></name></person-group><article-title>Efflux-mediated drug resistance in bacteria: an update</article-title><source>Drugs</source><year>2009</year><volume>69</volume><fpage>1555</fpage><lpage>1623</lpage><?supplied-pmid 19678712?><pub-id pub-id-type="pmid">19678712</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Hay SI, Rao PC, Dolecek C, Day NP, Stergachis A, Lopez AD, Murray CJ: Measuring and mapping &#x0200e;the global burden of antimicrobial resistance. BMC medicine 2018, 16(1):78.&#x0200e;<pub-id pub-id-type="pmid">19678712</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Delcour</surname><given-names>AH</given-names></name></person-group><article-title>Outer membrane permeability and antibiotic resistance</article-title><source>Biochim Biophys Acta</source><year>2009</year><volume>1794</volume><issue>5</issue><fpage>808</fpage><lpage>16</lpage><?supplied-pmid 19100346?><pub-id pub-id-type="pmid">19100346</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta. 2009;1794(5):808&#x02013;16.<pub-id pub-id-type="pmid">19100346</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Laxminarayan</surname><given-names>R</given-names></name><name><surname>Duse</surname><given-names>A</given-names></name><name><surname>Wattal</surname><given-names>C</given-names></name><name><surname>Zaidi</surname><given-names>AK</given-names></name><name><surname>Wertheim</surname><given-names>HF</given-names></name><name><surname>Sumpradit</surname><given-names>N</given-names></name><etal/></person-group><article-title>Antibiotic resistance&#x02014;the need for global solutions</article-title><source>Lancet Infect Dis</source><year>2013</year><volume>13</volume><issue>12</issue><fpage>1057</fpage><lpage>1098</lpage><?supplied-pmid 24252483?><pub-id pub-id-type="pmid">24252483</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance&#x02014;the need for global solutions. Lancet Infect Dis. 2013;13(12):1057&#x02013;98.<pub-id pub-id-type="pmid">24252483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras J-B, Barbu EM, et al. Phylogenetic distribution of CRISPR-Cas systems in antibiotic-resistant Pseudomonas aeruginosa. MBio. 2015;6(6). 10.1128/mBio.01796-15.</mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Allegranzi</surname><given-names>B</given-names></name><name><surname>Gayet-Ageron</surname><given-names>A</given-names></name><name><surname>Damani</surname><given-names>N</given-names></name><name><surname>Bengaly</surname><given-names>L</given-names></name><name><surname>McLaws</surname><given-names>M-L</given-names></name><name><surname>Moro</surname><given-names>M-L</given-names></name><etal/></person-group><article-title>Global implementation of WHO's multimodal strategy for improvement of hand hygiene: a quasi-experimental study</article-title><source>Lancet Infect Dis</source><year>2013</year><volume>13</volume><issue>10</issue><fpage>843</fpage><lpage>851</lpage><?supplied-pmid 23972825?><pub-id pub-id-type="pmid">23972825</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Allegranzi B, Gayet-Ageron A, Damani N, Bengaly L, McLaws M-L, Moro M-L, et al. Global implementation of WHO&#x02019;s multimodal strategy for improvement of hand hygiene: a quasi-experimental study. Lancet Infect Dis. 2013;13(10):843&#x02013;51.<pub-id pub-id-type="pmid">23972825</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>T&#x000e4;ngd&#x000e9;n</surname><given-names>T</given-names></name><name><surname>Giske</surname><given-names>C</given-names></name></person-group><article-title>Global dissemination of extensively drug-resistant carbapenemase-producing <italic>E</italic> nterobacteriaceae: clinical perspectives on detection, treatment and infection control</article-title><source>J Intern Med</source><year>2015</year><volume>277</volume><issue>5</issue><fpage>501</fpage><lpage>512</lpage><?supplied-pmid 25556628?><pub-id pub-id-type="pmid">25556628</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">T&#x000e4;ngd&#x000e9;n T, Giske C. Global dissemination of extensively drug-resistant carbapenemase-producing <italic>E</italic> nterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med. 2015;277(5):501&#x02013;12.<pub-id pub-id-type="pmid">25556628</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Laxminarayan R, Impalli I, Rangarajan R, Cohn J, Ramjeet K, Trainor BW, Strathdee S, Sumpradit N, &#x0200e;Berman D, Wertheim H: Expanding antibiotic, vaccine, and diagnostics development and access &#x0200e;to tackle antimicrobial resistance. The Lancet 2024;403(10443):2534&#x02013;2550.&#x0200e;</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Spellberg</surname><given-names>B</given-names></name><name><surname>Guidos</surname><given-names>R</given-names></name><name><surname>Gilbert</surname><given-names>D</given-names></name><name><surname>Bradley</surname><given-names>J</given-names></name><name><surname>Boucher</surname><given-names>HW</given-names></name><name><surname>Scheld</surname><given-names>WM</given-names></name><etal/></person-group><article-title>The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America</article-title><source>Clin Infect Dis</source><year>2008</year><volume>46</volume><issue>2</issue><fpage>155</fpage><lpage>164</lpage><?supplied-pmid 18171244?><pub-id pub-id-type="pmid">18171244</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(2):155&#x02013;64.<pub-id pub-id-type="pmid">18171244</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Dyar</surname><given-names>O</given-names></name><name><surname>Pagani</surname><given-names>L</given-names></name><name><surname>Pulcini</surname><given-names>C</given-names></name></person-group><article-title>Strategies and challenges of antimicrobial stewardship in long-term care facilities</article-title><source>Clin Microbiol Infect</source><year>2015</year><volume>21</volume><issue>1</issue><fpage>10</fpage><lpage>19</lpage><?supplied-pmid 25636921?><pub-id pub-id-type="pmid">25636921</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Dyar O, Pagani L, Pulcini C. Strategies and challenges of antimicrobial stewardship in long-term care facilities. Clin Microbiol Infect. 2015;21(1):10&#x02013;9.<pub-id pub-id-type="pmid">25636921</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Coates</surname><given-names>AR</given-names></name><name><surname>Halls</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name></person-group><article-title>Novel classes of antibiotics or more of the same?</article-title><source>Br J Pharmacol</source><year>2011</year><volume>163</volume><issue>1</issue><fpage>184</fpage><lpage>194</lpage><?supplied-pmid 21323894?><pub-id pub-id-type="pmid">21323894</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br J Pharmacol. 2011;163(1):184&#x02013;94.<pub-id pub-id-type="pmid">21323894</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>P</given-names></name><name><surname>Sirisha</surname><given-names>VL</given-names></name></person-group><article-title>From gene editing to biofilm busting: CRISPR-CAS9 against antibiotic resistance&#x02014;a review</article-title><source>Cell Biochem Biophys</source><year>2024</year><volume>82</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">38182861</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Pandey P, Sirisha VL. From gene editing to biofilm busting: CRISPR-CAS9 against antibiotic resistance&#x02014;a review. Cell Biochem Biophys. 2024;82:1&#x02013;12.<pub-id pub-id-type="pmid">38182861</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Juszczuk-Kubiak</surname><given-names>E</given-names></name></person-group><article-title>Molecular aspects of the functioning of pathogenic bacteria biofilm based on quorum sensing (QS) signal-response system and innovative non-antibiotic strategies for their elimination</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><issue>5</issue><fpage>2655</fpage><?supplied-pmid 38473900?><pub-id pub-id-type="pmid">38473900</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Juszczuk-Kubiak E. Molecular aspects of the functioning of pathogenic bacteria biofilm based on quorum sensing (QS) signal-response system and innovative non-antibiotic strategies for their elimination. Int J Mol Sci. 2024;25(5):2655.<pub-id pub-id-type="pmid">38473900</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Saharan</surname><given-names>B</given-names></name><name><surname>Beniwal</surname><given-names>N</given-names></name><name><surname>Duhan</surname><given-names>J</given-names></name></person-group><article-title>From formulation to function: a detailed review of microbial biofilms and their polymer-based extracellular substances</article-title><source>The Microbe</source><year>2024</year><volume>5</volume><fpage>100194</fpage></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Saharan B, Beniwal N, Duhan J. From formulation to function: a detailed review of microbial biofilms and their polymer-based extracellular substances. The Microbe. 2024;5:100194.</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Costerton</surname><given-names>JW</given-names></name><name><surname>Stewart</surname><given-names>PS</given-names></name><name><surname>Greenberg</surname><given-names>EP</given-names></name></person-group><article-title>Bacterial biofilms: a common cause of persistent infections</article-title><source>Science</source><year>1999</year><volume>284</volume><issue>5418</issue><fpage>1318</fpage><lpage>1322</lpage><?supplied-pmid 10334980?><pub-id pub-id-type="pmid">10334980</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318&#x02013;22.<pub-id pub-id-type="pmid">10334980</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>W</given-names></name></person-group><article-title>Biofilms, antibiotics and penetration</article-title><source>Rev Med Microbiol</source><year>1991</year><volume>2</volume><fpage>177</fpage><lpage>181</lpage></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Nichols W. Biofilms, antibiotics and penetration. Rev Med Microbiol. 1991;2:177&#x02013;81.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Teng</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name></person-group><article-title>Nanomaterial-enabled anti-biofilm strategies: new opportunities for treatment of bacterial infections</article-title><source>Nanoscale</source><year>2025</year><volume>17</volume><issue>10</issue><fpage>5605</fpage><lpage>5628</lpage><?supplied-pmid 39918303?><pub-id pub-id-type="pmid">39918303</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Xie Y, Liu H, Teng Z, Ma J, Liu G. Nanomaterial-enabled anti-biofilm strategies: new opportunities for treatment of bacterial infections. Nanoscale. 2025;17(10):5605&#x02013;28.<pub-id pub-id-type="pmid">39918303</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Domenech</surname><given-names>M</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>E</given-names></name><name><surname>Moscoso</surname><given-names>M</given-names></name></person-group><article-title>Biofilm formation in <italic>Streptococcus pneumoniae</italic></article-title><source>Microb Biotechnol</source><year>2012</year><volume>5</volume><issue>4</issue><fpage>455</fpage><lpage>465</lpage><?supplied-pmid 21906265?><pub-id pub-id-type="pmid">21906265</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Domenech M, Garc&#x000ed;a E, Moscoso M. Biofilm formation in <italic>Streptococcus pneumoniae</italic>. Microb Biotechnol. 2012;5(4):455&#x02013;65.<pub-id pub-id-type="pmid">21906265</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Balc&#x000e1;zar</surname><given-names>JL</given-names></name><name><surname>Subirats</surname><given-names>J</given-names></name><name><surname>Borrego</surname><given-names>CM</given-names></name></person-group><article-title>The role of biofilms as environmental reservoirs of antibiotic resistance</article-title><source>Front Microbiol</source><year>2015</year><volume>6</volume><fpage>1216</fpage><?supplied-pmid 26583011?><pub-id pub-id-type="pmid">26583011</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Balc&#x000e1;zar JL, Subirats J, Borrego CM. The role of biofilms as environmental reservoirs of antibiotic resistance. Front Microbiol. 2015;6:1216.<pub-id pub-id-type="pmid">26583011</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Keren</surname><given-names>I</given-names></name><name><surname>Kaldalu</surname><given-names>N</given-names></name><name><surname>Spoering</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name></person-group><article-title>Persister cells and tolerance to antimicrobials</article-title><source>FEMS Microbiol Lett</source><year>2004</year><volume>230</volume><issue>1</issue><fpage>13</fpage><lpage>18</lpage><?supplied-pmid 14734160?><pub-id pub-id-type="pmid">14734160</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett. 2004;230(1):13&#x02013;8.<pub-id pub-id-type="pmid">14734160</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x000e1;</surname><given-names>K</given-names></name></person-group><article-title>Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses</article-title><source>J Dent Res</source><year>2010</year><volume>89</volume><issue>3</issue><fpage>205</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">20139339</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">J&#x000e1; K. Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. J Dent Res. 2010;89(3):205&#x02013;18.<pub-id pub-id-type="pmid">20139339</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Patriquin</surname><given-names>GM</given-names></name><name><surname>Banin</surname><given-names>E</given-names></name><name><surname>Gilmour</surname><given-names>C</given-names></name><name><surname>Tuchman</surname><given-names>R</given-names></name><name><surname>Greenberg</surname><given-names>EP</given-names></name><name><surname>Poole</surname><given-names>K</given-names></name></person-group><article-title>Influence of quorum sensing and iron on twitching motility and biofilm formation in <italic>Pseudomonas aeruginosa</italic></article-title><source>J Bacteriol</source><year>2008</year><volume>190</volume><issue>2</issue><fpage>662</fpage><lpage>671</lpage><?supplied-pmid 17993517?><pub-id pub-id-type="pmid">17993517</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Patriquin GM, Banin E, Gilmour C, Tuchman R, Greenberg EP, Poole K. Influence of quorum sensing and iron on twitching motility and biofilm formation in <italic>Pseudomonas aeruginosa</italic>. J Bacteriol. 2008;190(2):662&#x02013;71.<pub-id pub-id-type="pmid">17993517</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Abebe</surname><given-names>GM</given-names></name></person-group><article-title>The role of bacterial biofilm in antibiotic resistance and food contamination</article-title><source>Int J Microbiol</source><year>2020</year><volume>2020</volume><issue>1</issue><fpage>1705814</fpage><?supplied-pmid 32908520?><pub-id pub-id-type="pmid">32908520</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Abebe GM. The role of bacterial biofilm in antibiotic resistance and food contamination. Int J Microbiol. 2020;2020(1):1705814.<pub-id pub-id-type="pmid">32908520</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Hancock</surname><given-names>RE</given-names></name><name><surname>Speert</surname><given-names>DP</given-names></name></person-group><article-title>Antibiotic resistance in <italic>Pseudomonas aeruginosa</italic>: mechanisms and impact on treatment</article-title><source>Drug Resist Updat</source><year>2000</year><volume>3</volume><issue>4</issue><fpage>247</fpage><lpage>255</lpage><?supplied-pmid 11498392?><pub-id pub-id-type="pmid">11498392</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Hancock RE, Speert DP. Antibiotic resistance in <italic>Pseudomonas aeruginosa</italic>: mechanisms and impact on treatment. Drug Resist Updat. 2000;3(4):247&#x02013;55.<pub-id pub-id-type="pmid">11498392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Redfern</surname><given-names>J</given-names></name><name><surname>Wallace</surname><given-names>J</given-names></name><name><surname>van Belkum</surname><given-names>A</given-names></name><name><surname>Jaillard</surname><given-names>M</given-names></name><name><surname>Whittard</surname><given-names>E</given-names></name><name><surname>Ragupathy</surname><given-names>R</given-names></name><etal/></person-group><article-title>Biofilm associated genotypes of multiple antibiotic resistant Pseudomonas aeruginosa</article-title><source>BMC Genomics</source><year>2021</year><volume>22</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">33388042</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Redfern J, Wallace J, van Belkum A, Jaillard M, Whittard E, Ragupathy R, et al. Biofilm associated genotypes of multiple antibiotic resistant Pseudomonas aeruginosa. BMC Genomics. 2021;22:1&#x02013;16.<pub-id pub-id-type="pmid">33388042</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name></person-group><article-title>Mechanisms and control strategies of antibiotic resistance in pathological biofilms</article-title><source>J Microbiol Biotechnol</source><year>2020</year><volume>31</volume><issue>1</issue><fpage>1</fpage></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Luo Y, Yang Q, Zhang D, Yan W. Mechanisms and control strategies of antibiotic resistance in pathological biofilms. J Microbiol Biotechnol. 2020;31(1):1.</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Haddad Kashani H, Schmelcher M, Sabzalipoor H, Seyed Hosseini E, Moniri R: Recombinant endolysins as potential therapeutics against antibiotic-resistant Staphylococcus aureus: current status of research and novel delivery strategies. Clinical microbiology reviews 2018;31(1). 10.1128/cmr.00071-00017.</mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Kashani</surname><given-names>HH</given-names></name><name><surname>Moniri</surname><given-names>R</given-names></name></person-group><article-title>Expression of recombinant pET22b-LysK-cysteine/histidine-dependent amidohydrolase/peptidase bacteriophage therapeutic protein in <italic>Escherichia coli</italic> BL21 (DE3)</article-title><source>Osong Public Health Res Perspect</source><year>2015</year><volume>6</volume><issue>4</issue><fpage>256</fpage><lpage>260</lpage><?supplied-pmid 26473093?><pub-id pub-id-type="pmid">26473093</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Kashani HH, Moniri R. Expression of recombinant pET22b-LysK-cysteine/histidine-dependent amidohydrolase/peptidase bacteriophage therapeutic protein in <italic>Escherichia coli</italic> BL21 (DE3). Osong Public Health Res Perspect. 2015;6(4):256&#x02013;60.<pub-id pub-id-type="pmid">26473093</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Hosseini</surname><given-names>ES</given-names></name><name><surname>Moniri</surname><given-names>R</given-names></name><name><surname>Goli</surname><given-names>YD</given-names></name><name><surname>Kashani</surname><given-names>HH</given-names></name></person-group><article-title>Purification of antibacterial CHAPK protein using a self-cleaving fusion tag and its activity against methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Probiotics Antimicrob Proteins</source><year>2016</year><volume>8</volume><issue>4</issue><fpage>202</fpage><lpage>210</lpage><?supplied-pmid 27797005?><pub-id pub-id-type="pmid">27797005</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Hosseini ES, Moniri R, Goli YD, Kashani HH. Purification of antibacterial CHAPK protein using a self-cleaving fusion tag and its activity against methicillin-resistant <italic>Staphylococcus aureus</italic>. Probiotics Antimicrob Proteins. 2016;8(4):202&#x02013;10.<pub-id pub-id-type="pmid">27797005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Van Hoogstraten S, Kuik C, Arts J, Cillero-Pastor B: Molecular imaging of bacterial biofilms&#x02014;a &#x0200e;systematic review. Critical reviews in microbiology 2024;50(6):971&#x02013;992.&#x0200e;</mixed-citation></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>CW</given-names></name><name><surname>Mah</surname><given-names>T-F</given-names></name></person-group><article-title>Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria</article-title><source>FEMS Microbiol Rev</source><year>2017</year><volume>41</volume><issue>3</issue><fpage>276</fpage><lpage>301</lpage><?supplied-pmid 28369412?><pub-id pub-id-type="pmid">28369412</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Hall CW, Mah T-F. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev. 2017;41(3):276&#x02013;301.<pub-id pub-id-type="pmid">28369412</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Wan</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Targeted elimination of bla NDM-5 gene in <italic>Escherichia coli</italic> by conjugative CRISPR-Cas9 system</article-title><source>Infect Drug Resist</source><year>2022</year><?supplied-pmid 36605851?><pub-id pub-id-type="pmid">36605851</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Li P, Wan P, Zhao R, Chen J, Li X, Li J, et al. Targeted elimination of bla NDM-5 gene in <italic>Escherichia coli</italic> by conjugative CRISPR-Cas9 system. Infect Drug Resist. 2022. 10.2147/IDR.S357470.<pub-id pub-id-type="pmid">36605851</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Marraffini</surname><given-names>LA</given-names></name></person-group><article-title>CRISPR-Cas immunity in prokaryotes</article-title><source>Nature</source><year>2015</year><volume>526</volume><issue>7571</issue><fpage>55</fpage><lpage>61</lpage><?supplied-pmid 26432244?><pub-id pub-id-type="pmid">26432244</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Marraffini LA. CRISPR-Cas immunity in prokaryotes. Nature. 2015;526(7571):55&#x02013;61.<pub-id pub-id-type="pmid">26432244</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Vigouroux A, Bikard D. CRISPR tools to control gene expression in bacteria. Microbiol Mol Biol Rev. 2020;84(2). 10.1128/MMBR.00077-19.</mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>V</given-names></name><name><surname>Gohil</surname><given-names>N</given-names></name><name><surname>Ramirez Garcia</surname><given-names>R</given-names></name><name><surname>Braddick</surname><given-names>D</given-names></name><name><surname>Fofi&#x000e9;</surname><given-names>CK</given-names></name></person-group><article-title>Recent advances in CRISPR-Cas9 genome editing technology for biological and biomedical investigations</article-title><source>J Cell Biochem</source><year>2018</year><volume>119</volume><issue>1</issue><fpage>81</fpage><lpage>94</lpage><?supplied-pmid 28544016?><pub-id pub-id-type="pmid">28544016</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Singh V, Gohil N, Ramirez Garcia R, Braddick D, Fofi&#x000e9; CK. Recent advances in CRISPR-Cas9 genome editing technology for biological and biomedical investigations. J Cell Biochem. 2018;119(1):81&#x02013;94.<pub-id pub-id-type="pmid">28544016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Sapranauskas</surname><given-names>R</given-names></name><name><surname>Gasiunas</surname><given-names>G</given-names></name><name><surname>Fremaux</surname><given-names>C</given-names></name><name><surname>Barrangou</surname><given-names>R</given-names></name><name><surname>Horvath</surname><given-names>P</given-names></name><name><surname>Siksnys</surname><given-names>V</given-names></name></person-group><article-title>The <italic>Streptococcus thermophilus</italic> CRISPR/Cas system provides immunity in <italic>Escherichia coli</italic></article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><issue>21</issue><fpage>9275</fpage><lpage>9282</lpage><?supplied-pmid 21813460?><pub-id pub-id-type="pmid">21813460</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Sapranauskas R, Gasiunas G, Fremaux C, Barrangou R, Horvath P, Siksnys V. The <italic>Streptococcus thermophilus</italic> CRISPR/Cas system provides immunity in <italic>Escherichia coli</italic>. Nucleic Acids Res. 2011;39(21):9275&#x02013;82.<pub-id pub-id-type="pmid">21813460</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Battalapalli</surname><given-names>D</given-names></name><name><surname>Hakeem</surname><given-names>MJ</given-names></name><name><surname>Selamneni</surname><given-names>V</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Draz</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections</article-title><source>J Nanobiotechnol</source><year>2021</year><volume>19</volume><fpage>1</fpage><lpage>26</lpage></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Wu Y, Battalapalli D, Hakeem MJ, Selamneni V, Zhang P, Draz MS, et al. Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections. J Nanobiotechnol. 2021;19:1&#x02013;26.</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Triple-targeting delivery of CRISPR/Cas9 to reduce the risk of cardiovascular diseases</article-title><source>Angew Chem Int Ed Engl</source><year>2019</year><volume>58</volume><issue>36</issue><fpage>12404</fpage><lpage>12408</lpage><?supplied-pmid 31318118?><pub-id pub-id-type="pmid">31318118</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Zhang L, Wang L, Xie Y, Wang P, Deng S, Qin A, et al. Triple-targeting delivery of CRISPR/Cas9 to reduce the risk of cardiovascular diseases. Angew Chem Int Ed Engl. 2019;58(36):12404&#x02013;8.<pub-id pub-id-type="pmid">31318118</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Timin</surname><given-names>AS</given-names></name><name><surname>Muslimov</surname><given-names>AR</given-names></name><name><surname>Lepik</surname><given-names>KV</given-names></name><name><surname>Epifanovskaya</surname><given-names>OS</given-names></name><name><surname>Shakirova</surname><given-names>AI</given-names></name><name><surname>Mock</surname><given-names>U</given-names></name><etal/></person-group><article-title>Efficient gene editing via non-viral delivery of CRISPR-Cas9 system using polymeric and hybrid microcarriers</article-title><source>Nanomedicine</source><year>2018</year><volume>14</volume><issue>1</issue><fpage>97</fpage><lpage>108</lpage><?supplied-pmid 28917642?><pub-id pub-id-type="pmid">28917642</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Timin AS, Muslimov AR, Lepik KV, Epifanovskaya OS, Shakirova AI, Mock U, et al. Efficient gene editing via non-viral delivery of CRISPR-Cas9 system using polymeric and hybrid microcarriers. Nanomedicine. 2018;14(1):97&#x02013;108.<pub-id pub-id-type="pmid">28917642</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Gratacap</surname><given-names>RL</given-names></name><name><surname>Regan</surname><given-names>T</given-names></name><name><surname>Dehler</surname><given-names>CE</given-names></name><name><surname>Martin</surname><given-names>SAM</given-names></name><name><surname>Boudinot</surname><given-names>P</given-names></name><name><surname>Collet</surname><given-names>B</given-names></name><etal/></person-group><article-title>Efficient CRISPR/Cas9 genome editing in a salmonid fish cell line using a lentivirus delivery system</article-title><source>BMC Biotechnol</source><year>2020</year><volume>20</volume><issue>1</issue><fpage>35</fpage><?supplied-pmid 32576161?><pub-id pub-id-type="pmid">32576161</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Gratacap RL, Regan T, Dehler CE, Martin SAM, Boudinot P, Collet B, et al. Efficient CRISPR/Cas9 genome editing in a salmonid fish cell line using a lentivirus delivery system. BMC Biotechnol. 2020;20(1):35.<pub-id pub-id-type="pmid">32576161</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name></person-group><article-title>Nanoparticles for CRISPR-Cas9 delivery</article-title><source>Nat Biomed Eng</source><year>2017</year><volume>1</volume><issue>11</issue><fpage>854</fpage><lpage>855</lpage><?supplied-pmid 30147994?><pub-id pub-id-type="pmid">30147994</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Glass Z, Li Y, Xu Q. Nanoparticles for CRISPR-Cas9 delivery. Nat Biomed Eng. 2017;1(11):854&#x02013;5.<pub-id pub-id-type="pmid">30147994</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Sago</surname><given-names>CD</given-names></name><name><surname>Lokugamage</surname><given-names>MP</given-names></name><name><surname>Paunovska</surname><given-names>K</given-names></name><name><surname>Vanover</surname><given-names>DA</given-names></name><name><surname>Monaco</surname><given-names>CM</given-names></name><name><surname>Shah</surname><given-names>NN</given-names></name><etal/></person-group><article-title>High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing</article-title><source>Proc Natl Acad Sci U S A</source><year>2018</year><volume>115</volume><issue>42</issue><fpage>E9944</fpage><lpage>E9952</lpage><?supplied-pmid 30275336?><pub-id pub-id-type="pmid">30275336</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Sago CD, Lokugamage MP, Paunovska K, Vanover DA, Monaco CM, Shah NN, et al. High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing. Proc Natl Acad Sci U S A. 2018;115(42):E9944&#x02013;52.<pub-id pub-id-type="pmid">30275336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Shao</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>Gene silencing through CRISPR interference in bacteria: current advances and future prospects</article-title><source>Front Microbiol</source><year>2021</year><volume>12</volume><fpage>635227</fpage><?supplied-pmid 33868193?><pub-id pub-id-type="pmid">33868193</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Zhang R, Xu W, Shao S, Wang Q. Gene silencing through CRISPR interference in bacteria: current advances and future prospects. Front Microbiol. 2021;12:635227.<pub-id pub-id-type="pmid">33868193</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Panda</surname><given-names>S</given-names></name><name><surname>Gonzales-Rojas</surname><given-names>R</given-names></name><name><surname>Chong</surname><given-names>A</given-names></name><name><surname>Bugay</surname><given-names>V</given-names></name><etal/></person-group><article-title>Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours</article-title><source>Nat Biomed Eng</source><year>2018</year><volume>2</volume><issue>7</issue><fpage>497</fpage><lpage>507</lpage><?supplied-pmid 30948824?><pub-id pub-id-type="pmid">30948824</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Lee B, Lee K, Panda S, Gonzales-Rojas R, Chong A, Bugay V, et al. Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours. Nat Biomed Eng. 2018;2(7):497&#x02013;507.<pub-id pub-id-type="pmid">30948824</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>CF</given-names></name><name><surname>Luo</surname><given-names>YL</given-names></name><name><surname>Lu</surname><given-names>ZD</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy</article-title><source>Biomater Sci</source><year>2018</year><volume>6</volume><issue>6</issue><fpage>1592</fpage><lpage>1603</lpage><?supplied-pmid 29725684?><pub-id pub-id-type="pmid">29725684</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Liu Y, Zhao G, Xu CF, Luo YL, Lu ZD, Wang J. Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy. Biomater Sci. 2018;6(6):1592&#x02013;603.<pub-id pub-id-type="pmid">29725684</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Shahbazi</surname><given-names>R</given-names></name><name><surname>Sghia-Hughes</surname><given-names>G</given-names></name><name><surname>Reid</surname><given-names>JL</given-names></name><name><surname>Kubek</surname><given-names>S</given-names></name><name><surname>Haworth</surname><given-names>KG</given-names></name><name><surname>Humbert</surname><given-names>O</given-names></name><etal/></person-group><article-title>Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations</article-title><source>Nat Mater</source><year>2019</year><volume>18</volume><issue>10</issue><fpage>1124</fpage><lpage>1132</lpage><?supplied-pmid 31133730?><pub-id pub-id-type="pmid">31133730</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Shahbazi R, Sghia-Hughes G, Reid JL, Kubek S, Haworth KG, Humbert O, et al. Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations. Nat Mater. 2019;18(10):1124&#x02013;32.<pub-id pub-id-type="pmid">31133730</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Kadkhoda</surname><given-names>H</given-names></name><name><surname>Gholizadeh</surname><given-names>P</given-names></name><name><surname>Kafil</surname><given-names>HS</given-names></name><name><surname>Ghotaslou</surname><given-names>R</given-names></name><name><surname>Pirzadeh</surname><given-names>T</given-names></name><name><surname>Rezaee</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Role of CRISPR-Cas systems and anti-CRISPR proteins in bacterial antibiotic resistance</article-title><source>Heliyon</source><year>2024</year><?supplied-pmid 39149034?><pub-id pub-id-type="pmid">39149034</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Kadkhoda H, Gholizadeh P, Kafil HS, Ghotaslou R, Pirzadeh T, Rezaee MA, et al. Role of CRISPR-Cas systems and anti-CRISPR proteins in bacterial antibiotic resistance. Heliyon. 2024. 10.1016/j.heliyon.2024.e34692.<pub-id pub-id-type="pmid">39149034</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Bhattacharjee</surname><given-names>R</given-names></name><name><surname>Nandi</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>A</given-names></name><name><surname>Kar</surname><given-names>S</given-names></name><name><surname>Manoharan</surname><given-names>N</given-names></name><etal/></person-group><article-title>Phage delivered CRISPR-Cas system to combat multidrug-resistant pathogens in gut microbiome</article-title><source>Biomed Pharmacother</source><year>2022</year><volume>151</volume><fpage>113122</fpage><?supplied-pmid 35594718?><pub-id pub-id-type="pmid">35594718</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Nath A, Bhattacharjee R, Nandi A, Sinha A, Kar S, Manoharan N, et al. Phage delivered CRISPR-Cas system to combat multidrug-resistant pathogens in gut microbiome. Biomed Pharmacother. 2022;151:113122.<pub-id pub-id-type="pmid">35594718</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>La Russa</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>LS</given-names></name></person-group><article-title>CRISPR/Cas9 in genome editing and beyond</article-title><source>Annu Rev Biochem</source><year>2016</year><volume>85</volume><issue>1</issue><fpage>227</fpage><lpage>264</lpage><?supplied-pmid 27145843?><pub-id pub-id-type="pmid">27145843</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Wang H, La Russa M, Qi LS. CRISPR/Cas9 in genome editing and beyond. Annu Rev Biochem. 2016;85(1):227&#x02013;64.<pub-id pub-id-type="pmid">27145843</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Asmamaw</surname><given-names>M</given-names></name><name><surname>Zawdie</surname><given-names>B</given-names></name></person-group><article-title>Mechanism and applications of CRISPR/Cas-9-mediated genome editing</article-title><source>Biologics</source><year>2021</year><volume>15</volume><fpage>353</fpage><lpage>61</lpage><?supplied-pmid 34456559?><pub-id pub-id-type="pmid">34456559</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Asmamaw M, Zawdie B. Mechanism and applications of CRISPR/Cas-9-mediated genome editing. Biologics. 2021;15:353&#x02013;61.<pub-id pub-id-type="pmid">34456559</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Barrangou</surname><given-names>R</given-names></name><name><surname>Fremaux</surname><given-names>C</given-names></name><name><surname>Deveau</surname><given-names>H</given-names></name><name><surname>Richards</surname><given-names>M</given-names></name><name><surname>Boyaval</surname><given-names>P</given-names></name><name><surname>Moineau</surname><given-names>S</given-names></name><etal/></person-group><article-title>CRISPR provides acquired resistance against viruses in prokaryotes</article-title><source>Science</source><year>2007</year><volume>315</volume><issue>5819</issue><fpage>1709</fpage><lpage>1712</lpage><?supplied-pmid 17379808?><pub-id pub-id-type="pmid">17379808</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315(5819):1709&#x02013;12.<pub-id pub-id-type="pmid">17379808</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="other">Angel PASRY, Raghul M, Gowsalya S, Paulkumar K, Murugan K: CRISPR interference system: a &#x0200e;potential strategy to inhibit pathogenic biofilm in the agri-food sector. In: CRISPR and RNAi &#x0200e;Systems. edn.: Elsevier; 2021:387&#x02013;403.&#x0200e;</mixed-citation></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J-S</given-names></name><name><surname>Cho</surname><given-names>D-H</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>W-J</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name><name><surname>Ko</surname><given-names>KS</given-names></name><etal/></person-group><article-title>CRISPR/Cas9-mediated re-sensitization of antibiotic-resistant <italic>Escherichia coli</italic> harboring extended-spectrum &#x003b2;-lactamases</article-title><source>J Microbiol Biotechnol</source><year>2016</year><volume>26</volume><issue>2</issue><fpage>394</fpage><lpage>401</lpage><?supplied-pmid 26502735?><pub-id pub-id-type="pmid">26502735</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Kim J-S, Cho D-H, Park M, Chung W-J, Shin D, Ko KS, et al. CRISPR/Cas9-mediated re-sensitization of antibiotic-resistant <italic>Escherichia coli</italic> harboring extended-spectrum &#x003b2;-lactamases. J Microbiol Biotechnol. 2016;26(2):394&#x02013;401.<pub-id pub-id-type="pmid">26502735</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name></person-group><article-title>The application of the CRISPR-Cas system in antibiotic resistance</article-title><source>Infect Drug Resist</source><year>2022</year><?supplied-pmid 36483141?><pub-id pub-id-type="pmid">36483141</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Tao S, Chen H, Li N, Liang W. The application of the CRISPR-Cas system in antibiotic resistance. Infect Drug Resist. 2022. 10.2147/IDR.S370869.<pub-id pub-id-type="pmid">36483141</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Palacios Araya</surname><given-names>D</given-names></name><name><surname>Palmer</surname><given-names>KL</given-names></name><name><surname>Duerkop</surname><given-names>BA</given-names></name></person-group><article-title>Crispr-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria</article-title><source>PLoS Pathog</source><year>2021</year><volume>17</volume><issue>7</issue><fpage>e1009672</fpage><?supplied-pmid 34237097?><pub-id pub-id-type="pmid">34237097</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Palacios Araya D, Palmer KL, Duerkop BA. Crispr-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria. PLoS Pathog. 2021;17(7):e1009672.<pub-id pub-id-type="pmid">34237097</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Jia</surname><given-names>Y-Y</given-names></name><name><surname>Jing</surname><given-names>Z-W</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>S-Y</given-names></name><name><surname>Mei</surname><given-names>Q-B</given-names></name><etal/></person-group><article-title>Construction and optimization of pH-sensitive nanoparticle delivery system containing PLGA and UCCs-2 for targeted treatment of <italic>Helicobacter pylori</italic></article-title><source>Colloids Surf, B</source><year>2018</year><volume>164</volume><fpage>11</fpage><lpage>19</lpage></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Luo M, Jia Y-Y, Jing Z-W, Li C, Zhou S-Y, Mei Q-B, et al. Construction and optimization of pH-sensitive nanoparticle delivery system containing PLGA and UCCs-2 for targeted treatment of <italic>Helicobacter pylori</italic>. Colloids Surf, B. 2018;164:11&#x02013;9.</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Khambhati</surname><given-names>K</given-names></name><name><surname>Bhattacharjee</surname><given-names>G</given-names></name><name><surname>Gohil</surname><given-names>N</given-names></name><name><surname>Dhanoa</surname><given-names>GK</given-names></name><name><surname>Sagona</surname><given-names>AP</given-names></name><name><surname>Mani</surname><given-names>I</given-names></name><etal/></person-group><article-title>Phage engineering and phage-assisted CRISPR-Cas delivery to combat multidrug-resistant pathogens</article-title><source>Bioeng Transl Med</source><year>2023</year><volume>8</volume><issue>2</issue><fpage>e10381</fpage><?supplied-pmid 36925687?><pub-id pub-id-type="pmid">36925687</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Khambhati K, Bhattacharjee G, Gohil N, Dhanoa GK, Sagona AP, Mani I, et al. Phage engineering and phage-assisted CRISPR-Cas delivery to combat multidrug-resistant pathogens. Bioeng Transl Med. 2023;8(2):e10381.<pub-id pub-id-type="pmid">36925687</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Gli&#x0017a;niewicz</surname><given-names>M</given-names></name><name><surname>Mi&#x00142;ek</surname><given-names>D</given-names></name><name><surname>Olszewska</surname><given-names>P</given-names></name><name><surname>Czajkowski</surname><given-names>A</given-names></name><name><surname>Serwin</surname><given-names>N</given-names></name><name><surname>Cecerska-Hery&#x00107;</surname><given-names>E</given-names></name><etal/></person-group><article-title>Advances in bacteriophage-mediated strategies for combating polymicrobial biofilms</article-title><source>Front Microbiol</source><year>2024</year><volume>14</volume><fpage>1320345</fpage><?supplied-pmid 38249486?><pub-id pub-id-type="pmid">38249486</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Gli&#x0017a;niewicz M, Mi&#x00142;ek D, Olszewska P, Czajkowski A, Serwin N, Cecerska-Hery&#x00107; E, et al. Advances in bacteriophage-mediated strategies for combating polymicrobial biofilms. Front Microbiol. 2024;14:1320345.<pub-id pub-id-type="pmid">38249486</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Radovic-Moreno</surname><given-names>AF</given-names></name><name><surname>Lu</surname><given-names>TK</given-names></name><name><surname>Puscasu</surname><given-names>VA</given-names></name><name><surname>Yoon</surname><given-names>CJ</given-names></name><name><surname>Langer</surname><given-names>R</given-names></name><name><surname>Farokhzad</surname><given-names>OC</given-names></name></person-group><article-title>Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics</article-title><source>ACS Nano</source><year>2012</year><volume>6</volume><issue>5</issue><fpage>4279</fpage><lpage>4287</lpage><?supplied-pmid 22471841?><pub-id pub-id-type="pmid">22471841</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Radovic-Moreno AF, Lu TK, Puscasu VA, Yoon CJ, Langer R, Farokhzad OC. Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano. 2012;6(5):4279&#x02013;87.<pub-id pub-id-type="pmid">22471841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Zaman</surname><given-names>QU</given-names></name><name><surname>Chu</surname><given-names>W</given-names></name><name><surname>Hao</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Sang</surname><given-names>S-F</given-names></name><etal/></person-group><article-title>CRISPR/Cas9-mediated multiplex genome editing of JAGGED gene in <italic>Brassica napus</italic> L</article-title><source>Biomolecules</source><year>2019</year><volume>9</volume><issue>11</issue><fpage>725</fpage><?supplied-pmid 31726660?><pub-id pub-id-type="pmid">31726660</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Zaman QU, Chu W, Hao M, Shi Y, Sun M, Sang S-F, et al. CRISPR/Cas9-mediated multiplex genome editing of JAGGED gene in <italic>Brassica napus</italic> L. Biomolecules. 2019;9(11):725.<pub-id pub-id-type="pmid">31726660</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Bondy-Denomy</surname><given-names>J</given-names></name></person-group><article-title>Protein inhibitors of CRISPR-Cas9</article-title><source>ACS Chem Biol</source><year>2018</year><volume>13</volume><issue>2</issue><fpage>417</fpage><lpage>423</lpage><?supplied-pmid 29251498?><pub-id pub-id-type="pmid">29251498</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Bondy-Denomy J. Protein inhibitors of CRISPR-Cas9. ACS Chem Biol. 2018;13(2):417&#x02013;23.<pub-id pub-id-type="pmid">29251498</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Chabas</surname><given-names>H</given-names></name><name><surname>Nicot</surname><given-names>A</given-names></name><name><surname>Meaden</surname><given-names>S</given-names></name><name><surname>Westra</surname><given-names>ER</given-names></name><name><surname>Tremblay</surname><given-names>DM</given-names></name><name><surname>Pradier</surname><given-names>L</given-names></name><etal/></person-group><article-title>Variability in the durability of CRISPR-Cas immunity</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>2019</year><volume>374</volume><issue>1772</issue><fpage>20180097</fpage><?supplied-pmid 30905283?><pub-id pub-id-type="pmid">30905283</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Chabas H, Nicot A, Meaden S, Westra ER, Tremblay DM, Pradier L, et al. Variability in the durability of CRISPR-Cas immunity. Philos Trans R Soc Lond B Biol Sci. 2019;374(1772):20180097.<pub-id pub-id-type="pmid">30905283</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Aslam</surname><given-names>B</given-names></name><name><surname>Rasool</surname><given-names>M</given-names></name><name><surname>Idris</surname><given-names>A</given-names></name><name><surname>Muzammil</surname><given-names>S</given-names></name><name><surname>Alvi</surname><given-names>RF</given-names></name><name><surname>Khurshid</surname><given-names>M</given-names></name><etal/></person-group><article-title>CRISPR-Cas system: a potential alternative tool to cope antibiotic resistance</article-title><source>Antimicrob Resist Infect Control</source><year>2020</year><volume>9</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">31908772</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Aslam B, Rasool M, Idris A, Muzammil S, Alvi RF, Khurshid M, et al. CRISPR-Cas system: a potential alternative tool to cope antibiotic resistance. Antimicrob Resist Infect Control. 2020;9:1&#x02013;3.<pub-id pub-id-type="pmid">31908772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><mixed-citation publication-type="other">Ortiz-Cartagena C, Fern&#x000e1;ndez-Grela P, Arm&#x000e1;n L, Blasco L, Pablo-Marcos D, Bleriot I, Fern&#x000e1;ndez-&#x0200e;Garc&#x000ed;a L, Ibarguren-Quiles C, Fern&#x000e1;ndez-Cuenca F, Barrio-Pujante A:.The LAMP-CRISPR-Cas13a &#x0200e;technique for detecting the CBASS mechanism of phage resistance in bacteria. Frontiers in &#x0200e;Microbiology. 2025;16:1550534.&#x0200e;</mixed-citation></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Saleh</surname><given-names>NM</given-names></name><name><surname>Das</surname><given-names>R</given-names></name><name><surname>Landis</surname><given-names>RF</given-names></name><name><surname>Bigdeli</surname><given-names>A</given-names></name><name><surname>Motamedchaboki</surname><given-names>K</given-names></name><etal/></person-group><article-title>Synergistic antimicrobial therapy using nanoparticles and antibiotics for the treatment of multidrug-resistant bacterial infection</article-title><source>Nano Futures</source><year>2017</year><volume>1</volume><issue>1</issue><fpage>015004</fpage></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Gupta A, Saleh NM, Das R, Landis RF, Bigdeli A, Motamedchaboki K, et al. Synergistic antimicrobial therapy using nanoparticles and antibiotics for the treatment of multidrug-resistant bacterial infection. Nano Futures. 2017;1(1):015004.</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Fatima</surname><given-names>F</given-names></name><name><surname>Siddiqui</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>WA</given-names></name></person-group><article-title>Nanoparticles as novel emerging therapeutic antibacterial agents in the antibiotics resistant era</article-title><source>Biol Trace Elem Res</source><year>2021</year><volume>199</volume><issue>7</issue><fpage>2552</fpage><lpage>2564</lpage><?supplied-pmid 33030657?><pub-id pub-id-type="pmid">33030657</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Fatima F, Siddiqui S, Khan WA. Nanoparticles as novel emerging therapeutic antibacterial agents in the antibiotics resistant era. Biol Trace Elem Res. 2021;199(7):2552&#x02013;64.<pub-id pub-id-type="pmid">33030657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Mulens-Arias</surname><given-names>V</given-names></name><name><surname>Rojas</surname><given-names>JM</given-names></name><name><surname>Barber</surname><given-names>DF</given-names></name></person-group><article-title>The intrinsic biological identities of iron oxide nanoparticles and their coatings: unexplored territory for combinatorial therapies</article-title><source>Nanomaterials</source><year>2020</year><volume>10</volume><issue>5</issue><fpage>837</fpage><?supplied-pmid 32349362?><pub-id pub-id-type="pmid">32349362</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Mulens-Arias V, Rojas JM, Barber DF. The intrinsic biological identities of iron oxide nanoparticles and their coatings: unexplored territory for combinatorial therapies. Nanomaterials. 2020;10(5):837.<pub-id pub-id-type="pmid">32349362</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="book"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>EM</given-names></name><name><surname>Borah</surname><given-names>A</given-names></name><name><surname>Sakthi</surname><given-names>KD</given-names></name></person-group><source>CRISPR/Cas9 Nano-delivery Approaches for Targeted Gene Therapy</source><year>2022</year><publisher-loc>Pharmaceutical Nanobiotechnology for Targeted Therapy</publisher-loc><publisher-name>Springer</publisher-name><fpage>27</fpage><lpage>64</lpage></element-citation><mixed-citation id="mc-CR80" publication-type="book">Jacob EM, Borah A, Sakthi KD. CRISPR/Cas9 Nano-delivery Approaches for Targeted Gene Therapy. Pharmaceutical Nanobiotechnology for Targeted Therapy: Springer; 2022. p. 27&#x02013;64.</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Karimi</surname><given-names>M</given-names></name><name><surname>Ghasemi</surname><given-names>A</given-names></name><name><surname>Zangabad</surname><given-names>PS</given-names></name><name><surname>Rahighi</surname><given-names>R</given-names></name><name><surname>Basri</surname><given-names>SMM</given-names></name><name><surname>Mirshekari</surname><given-names>H</given-names></name><etal/></person-group><article-title>Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems</article-title><source>Chem Soc Rev</source><year>2016</year><volume>45</volume><issue>5</issue><fpage>1457</fpage><lpage>1501</lpage><?supplied-pmid 26776487?><pub-id pub-id-type="pmid">26776487</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Karimi M, Ghasemi A, Zangabad PS, Rahighi R, Basri SMM, Mirshekari H, et al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev. 2016;45(5):1457&#x02013;501.<pub-id pub-id-type="pmid">26776487</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Chavanpatil</surname><given-names>MD</given-names></name><name><surname>Khdair</surname><given-names>A</given-names></name><name><surname>Panyam</surname><given-names>J</given-names></name></person-group><article-title>Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery</article-title><source>J Nanosci Nanotechnol</source><year>2006</year><volume>6</volume><issue>9&#x02013;10</issue><fpage>2651</fpage><lpage>2663</lpage><?supplied-pmid 17048473?><pub-id pub-id-type="pmid">17048473</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Chavanpatil MD, Khdair A, Panyam J. Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery. J Nanosci Nanotechnol. 2006;6(9&#x02013;10):2651&#x02013;63.<pub-id pub-id-type="pmid">17048473</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Anarjan</surname><given-names>FS</given-names></name></person-group><article-title>Active targeting drug delivery nanocarriers: Ligands</article-title><source>Nano Struct Nano Objects</source><year>2019</year><volume>19</volume><fpage>100370</fpage></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Anarjan FS. Active targeting drug delivery nanocarriers: Ligands. Nano Struct Nano Objects. 2019;19:100370.</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Pack</surname><given-names>DW</given-names></name><name><surname>Hoffman</surname><given-names>AS</given-names></name><name><surname>Pun</surname><given-names>S</given-names></name><name><surname>Stayton</surname><given-names>PS</given-names></name></person-group><article-title>Design and development of polymers for gene delivery</article-title><source>Nat Rev Drug Discovery</source><year>2005</year><volume>4</volume><issue>7</issue><fpage>581</fpage><lpage>593</lpage><?supplied-pmid 16052241?><pub-id pub-id-type="pmid">16052241</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discovery. 2005;4(7):581&#x02013;93.<pub-id pub-id-type="pmid">16052241</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Almeciga-Diaz</surname><given-names>CJ</given-names></name><name><surname>Barrera</surname><given-names>LA</given-names></name></person-group><article-title>Design and applications of gene therapy vectors for mucopolysaccharidosis in Colombia</article-title><source>Gene Ther</source><year>2020</year><volume>27</volume><issue>1</issue><fpage>104</fpage><lpage>107</lpage><?supplied-pmid 31267008?><pub-id pub-id-type="pmid">31267008</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Almeciga-Diaz CJ, Barrera LA. Design and applications of gene therapy vectors for mucopolysaccharidosis in Colombia. Gene Ther. 2020;27(1):104&#x02013;7.<pub-id pub-id-type="pmid">31267008</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Leal</surname><given-names>AF</given-names></name><name><surname>Cifuentes</surname><given-names>J</given-names></name><name><surname>Torres</surname><given-names>CE</given-names></name><name><surname>Su&#x000e1;rez</surname><given-names>D</given-names></name><name><surname>Quezada</surname><given-names>V</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Delivery and assessment of a CRISPR/nCas9-based genome editing system on <italic>in vitro</italic> models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>15045</fpage><?supplied-pmid 36057729?><pub-id pub-id-type="pmid">36057729</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Leal AF, Cifuentes J, Torres CE, Su&#x000e1;rez D, Quezada V, G&#x000f3;mez SC, et al. Delivery and assessment of a CRISPR/nCas9-based genome editing system on <italic>in vitro</italic> models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles. Sci Rep. 2022;12(1):15045.<pub-id pub-id-type="pmid">36057729</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Kuang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Stimuli-responsive gene delivery nanocarriers for cancer therapy</article-title><source>Nano Micro Lett</source><year>2023</year><volume>15</volume><issue>1</issue><fpage>44</fpage></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Zhang Q, Kuang G, Li W, Wang J, Ren H, Zhao Y. Stimuli-responsive gene delivery nanocarriers for cancer therapy. Nano Micro Lett. 2023;15(1):44.</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>BD</given-names></name><name><surname>Brooks</surname><given-names>AE</given-names></name></person-group><article-title>Therapeutic strategies to combat antibiotic resistance</article-title><source>Adv Drug Deliv Rev</source><year>2014</year><volume>78</volume><fpage>14</fpage><lpage>27</lpage><?supplied-pmid 25450262?><pub-id pub-id-type="pmid">25450262</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Brooks BD, Brooks AE. Therapeutic strategies to combat antibiotic resistance. Adv Drug Deliv Rev. 2014;78:14&#x02013;27.<pub-id pub-id-type="pmid">25450262</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Slavin</surname><given-names>YN</given-names></name><name><surname>Asnis</surname><given-names>J</given-names></name><name><surname>H&#x00144;feli</surname><given-names>UO</given-names></name><name><surname>Bach</surname><given-names>H</given-names></name></person-group><article-title>Metal nanoparticles: understanding the mechanisms behind antibacterial activity</article-title><source>J Nanobiotechnology</source><year>2017</year><volume>15</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">28049488</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Slavin YN, Asnis J, H&#x00144;feli UO, Bach H. Metal nanoparticles: understanding the mechanisms behind antibacterial activity. J Nanobiotechnology. 2017;15:1&#x02013;20.<pub-id pub-id-type="pmid">28049488</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Nagarajan</surname><given-names>P</given-names></name><name><surname>Subramaniyan</surname><given-names>V</given-names></name><name><surname>Elavarasan</surname><given-names>V</given-names></name><name><surname>Mohandoss</surname><given-names>N</given-names></name><name><surname>Subramaniyan</surname><given-names>P</given-names></name><name><surname>Vijayakumar</surname><given-names>S</given-names></name></person-group><article-title>Biofabricated aluminium oxide nanoparticles derived from <italic>Citrus aurantium</italic> L.: antimicrobial, anti-proliferation, and photocatalytic efficiencies</article-title><source>Sustainability</source><year>2023</year><volume>15</volume><issue>2</issue><fpage>1743</fpage></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Nagarajan P, Subramaniyan V, Elavarasan V, Mohandoss N, Subramaniyan P, Vijayakumar S. Biofabricated aluminium oxide nanoparticles derived from <italic>Citrus aurantium</italic> L.: antimicrobial, anti-proliferation, and photocatalytic efficiencies. Sustainability. 2023;15(2):1743.</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Flores-L&#x000f3;pez</surname><given-names>LZ</given-names></name><name><surname>Espinoza-G&#x000f3;mez</surname><given-names>H</given-names></name><name><surname>Somanathan</surname><given-names>R</given-names></name></person-group><article-title>Silver nanoparticles: electron transfer, reactive oxygen species, oxidative stress, beneficial and toxicological effects</article-title><source>J Appl Toxicol</source><year>2019</year><volume>39</volume><issue>1</issue><fpage>16</fpage><lpage>26</lpage><?supplied-pmid 29943411?><pub-id pub-id-type="pmid">29943411</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Flores-L&#x000f3;pez LZ, Espinoza-G&#x000f3;mez H, Somanathan R. Silver nanoparticles: electron transfer, reactive oxygen species, oxidative stress, beneficial and toxicological effects. J Appl Toxicol. 2019;39(1):16&#x02013;26.<pub-id pub-id-type="pmid">29943411</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>SS</given-names></name><name><surname>Ullah</surname><given-names>I</given-names></name><name><surname>Ullah</surname><given-names>S</given-names></name><name><surname>An</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Nie</surname><given-names>K</given-names></name><etal/></person-group><article-title>Recent advances in the surface functionalization of nanomaterials for antimicrobial applications</article-title><source>Materials</source><year>2021</year><volume>14</volume><issue>22</issue><fpage>6932</fpage><?supplied-pmid 34832332?><pub-id pub-id-type="pmid">34832332</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Khan SS, Ullah I, Ullah S, An R, Xu H, Nie K, et al. Recent advances in the surface functionalization of nanomaterials for antimicrobial applications. Materials. 2021;14(22):6932.<pub-id pub-id-type="pmid">34832332</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Fabrega</surname><given-names>J</given-names></name><name><surname>Fawcett</surname><given-names>SR</given-names></name><name><surname>Renshaw</surname><given-names>JC</given-names></name><name><surname>Lead</surname><given-names>JR</given-names></name></person-group><article-title>Silver nanoparticle impact on bacterial growth: effect of pH, concentration, and organic matter</article-title><source>Environ Sci Technol</source><year>2009</year><volume>43</volume><issue>19</issue><fpage>7285</fpage><lpage>7290</lpage><?supplied-pmid 19848135?><pub-id pub-id-type="pmid">19848135</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Fabrega J, Fawcett SR, Renshaw JC, Lead JR. Silver nanoparticle impact on bacterial growth: effect of pH, concentration, and organic matter. Environ Sci Technol. 2009;43(19):7285&#x02013;90.<pub-id pub-id-type="pmid">19848135</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Murthy</surname><given-names>SK</given-names></name></person-group><article-title>Nanoparticles in modern medicine: state of the art and future challenges</article-title><source>Int J Nanomed</source><year>2007</year><volume>2</volume><issue>2</issue><fpage>129</fpage><lpage>141</lpage></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Murthy SK. Nanoparticles in modern medicine: state of the art and future challenges. Int J Nanomed. 2007;2(2):129&#x02013;41.</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Targeted delivery of CRISPR/Cas9-mediated cancer gene therapy via liposome-templated hydrogel nanoparticles</article-title><source>Adv Funct Mater</source><year>2017</year><volume>27</volume><issue>46</issue><fpage>1703036</fpage><?supplied-pmid 29755309?><pub-id pub-id-type="pmid">29755309</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Chen Z, Liu F, Chen Y, Liu J, Wang X, Chen AT, et al. Targeted delivery of CRISPR/Cas9-mediated cancer gene therapy via liposome-templated hydrogel nanoparticles. Adv Funct Mater. 2017;27(46):1703036.<pub-id pub-id-type="pmid">29755309</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Chowdhry</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>SZ</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Godhulayyagari</surname><given-names>S</given-names></name><name><surname>Ebrahimi</surname><given-names>SB</given-names></name><name><surname>Samanta</surname><given-names>D</given-names></name></person-group><article-title>Enhancing CRISPR/Cas systems with nanotechnology</article-title><source>Trends Biotechnol</source><year>2023</year><volume>41</volume><issue>12</issue><fpage>1549</fpage><lpage>1564</lpage><?supplied-pmid 37451945?><pub-id pub-id-type="pmid">37451945</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Chowdhry R, Lu SZ, Lee S, Godhulayyagari S, Ebrahimi SB, Samanta D. Enhancing CRISPR/Cas systems with nanotechnology. Trends Biotechnol. 2023;41(12):1549&#x02013;64.<pub-id pub-id-type="pmid">37451945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Saw</surname><given-names>PE</given-names></name><name><surname>Cui</surname><given-names>Gh</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group><article-title>Nanoparticles-mediated CRISPR/Cas gene editing delivery system</article-title><source>ChemMedChem</source><year>2022</year><volume>17</volume><issue>9</issue><fpage>e202100777</fpage><?supplied-pmid 35261159?><pub-id pub-id-type="pmid">35261159</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Saw PE, Cui Gh, Xu X. Nanoparticles-mediated CRISPR/Cas gene editing delivery system. ChemMedChem. 2022;17(9):e202100777.<pub-id pub-id-type="pmid">35261159</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>P</given-names></name><name><surname>Vavilala</surname><given-names>SL</given-names></name></person-group><article-title>From gene editing to biofilm busting: CRISPR-CAS9 against antibiotic resistance&#x02014;a review</article-title><source>Cell Biochem Biophys</source><year>2024</year><volume>82</volume><issue>2</issue><fpage>549</fpage><lpage>560</lpage><?supplied-pmid 38702575?><pub-id pub-id-type="pmid">38702575</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Pandey P, Vavilala SL. From gene editing to biofilm busting: CRISPR-CAS9 against antibiotic resistance&#x02014;a review. Cell Biochem Biophys. 2024;82(2):549&#x02013;60.<pub-id pub-id-type="pmid">38702575</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Albanese</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>PS</given-names></name><name><surname>Chan</surname><given-names>WCW</given-names></name></person-group><article-title>The effect of nanoparticle size, shape, and surface chemistry on biological systems</article-title><source>Annu Rev Biomed Eng</source><year>2012</year><volume>14</volume><fpage>1</fpage><lpage>16</lpage><?supplied-pmid 22524388?><pub-id pub-id-type="pmid">22524388</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1&#x02013;16.<pub-id pub-id-type="pmid">22524388</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco</surname><given-names>E</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Ferrari</surname><given-names>M</given-names></name></person-group><article-title>Principles of nanoparticle design for overcoming biological barriers to drug delivery</article-title><source>Nat Biotechnol</source><year>2015</year><volume>33</volume><issue>9</issue><fpage>941</fpage><lpage>951</lpage><?supplied-pmid 26348965?><pub-id pub-id-type="pmid">26348965</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941&#x02013;51.<pub-id pub-id-type="pmid">26348965</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Schrand</surname><given-names>AM</given-names></name><name><surname>Rahman</surname><given-names>MF</given-names></name><name><surname>Hussain</surname><given-names>SM</given-names></name><name><surname>Schlager</surname><given-names>JJ</given-names></name><name><surname>Smith</surname><given-names>DA</given-names></name><name><surname>Syed</surname><given-names>AF</given-names></name></person-group><article-title>Metal-based nanoparticles and their toxicity assessment</article-title><source>WIREs Nanomed Nanobiotechnol</source><year>2010</year><volume>2</volume><issue>5</issue><fpage>544</fpage><lpage>568</lpage></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Schrand AM, Rahman MF, Hussain SM, Schlager JJ, Smith DA, Syed AF. Metal-based nanoparticles and their toxicity assessment. WIREs Nanomed Nanobiotechnol. 2010;2(5):544&#x02013;68.</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>E</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Mizoguchi</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>A</given-names></name><name><surname>Takanashi</surname><given-names>H</given-names></name><name><surname>Itoh</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Assessment of the carcinogenic potential of mitemcinal (GM-611): increased incidence of malignant lymphoma in a rat carcinogenicity study</article-title><source>Toxicol Appl Pharmacol</source><year>2008</year><volume>228</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><?supplied-pmid 18355581?><pub-id pub-id-type="pmid">18355581</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Fujii E, Kimura K, Mizoguchi K, Kato A, Takanashi H, Itoh Z, et al. Assessment of the carcinogenic potential of mitemcinal (GM-611): increased incidence of malignant lymphoma in a rat carcinogenicity study. Toxicol Appl Pharmacol. 2008;228(1):1&#x02013;7.<pub-id pub-id-type="pmid">18355581</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Kara</surname><given-names>G</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Ozpolat</surname><given-names>B</given-names></name></person-group><article-title>Rnai-based therapeutics and tumor targeted delivery in cancer</article-title><source>Adv Drug Deliv Rev</source><year>2022</year><volume>182</volume><fpage>114113</fpage><?supplied-pmid 35063535?><pub-id pub-id-type="pmid">35063535</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Kara G, Calin GA, Ozpolat B. Rnai-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022;182:114113.<pub-id pub-id-type="pmid">35063535</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>K</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR/Cas9-mediated programmed death-ligand 1 attenuation and chemotherapeutics-induced immunogenic cell death</article-title><source>ACS Appl Mater Interfaces</source><year>2020</year><volume>12</volume><issue>14</issue><fpage>16018</fpage><lpage>16030</lpage><?supplied-pmid 32192326?><pub-id pub-id-type="pmid">32192326</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Tu K, Deng H, Kong L, Wang Y, Yang T, Hu Q, et al. Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR/Cas9-mediated programmed death-ligand 1 attenuation and chemotherapeutics-induced immunogenic cell death. ACS Appl Mater Interfaces. 2020;12(14):16018&#x02013;30.<pub-id pub-id-type="pmid">32192326</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>S</given-names></name></person-group><article-title>External stimuli-responsive nanoparticles for spatially and temporally controlled delivery of CRISPR-Cas genome editors</article-title><source>Biomater Sci</source><year>2021</year><volume>9</volume><issue>18</issue><fpage>6012</fpage><lpage>6022</lpage><?supplied-pmid 34286726?><pub-id pub-id-type="pmid">34286726</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Xie R, Wang Y, Gong S. External stimuli-responsive nanoparticles for spatially and temporally controlled delivery of CRISPR-Cas genome editors. Biomater Sci. 2021;9(18):6012&#x02013;22.<pub-id pub-id-type="pmid">34286726</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>PH-Responsive polymeric nanocarriers for efficient killing of cariogenic bacteria in biofilms</article-title><source>Biomater Sci</source><year>2019</year><volume>7</volume><fpage>1643</fpage><lpage>1651</lpage><?supplied-pmid 30723851?><pub-id pub-id-type="pmid">30723851</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Zhao Z, Ding C, Wang Y, Tan H, Li J. PH-Responsive polymeric nanocarriers for efficient killing of cariogenic bacteria in biofilms. Biomater Sci. 2019;7:1643&#x02013;51.<pub-id pub-id-type="pmid">30723851</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>MHY</given-names></name><name><surname>Leung</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Strong</surname><given-names>C</given-names></name><name><surname>Basha</surname><given-names>G</given-names></name><name><surname>Momeni</surname><given-names>A</given-names></name><etal/></person-group><article-title>Induction of bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency</article-title><source>Adv Mater</source><year>2023</year><volume>35</volume><issue>31</issue><fpage>2303370</fpage></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Cheng MHY, Leung J, Zhang Y, Strong C, Basha G, Momeni A, et al. Induction of bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency. Adv Mater. 2023;35(31):2303370.</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>Y-T</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>H-Y</given-names></name><name><surname>Bian</surname><given-names>Z-x</given-names></name><etal/></person-group><article-title>CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><issue>7</issue><fpage>3329</fpage><?supplied-pmid 35547744?><pub-id pub-id-type="pmid">35547744</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">Chan Y-T, Lu Y, Wu J, Zhang C, Tan H-Y, Bian Z-x, et al. CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives. Theranostics. 2022;12(7):3329.<pub-id pub-id-type="pmid">35547744</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>B</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Screening for novel quorum-sensing inhibitors to interfere with the formation of <italic>Pseudomonas aeruginosa</italic> biofilm</article-title><source>J Med Microbiol</source><year>2011</year><volume>60</volume><issue>12</issue><fpage>1827</fpage><lpage>1834</lpage><?supplied-pmid 21852522?><pub-id pub-id-type="pmid">21852522</pub-id>
</element-citation><mixed-citation id="mc-CR109" publication-type="journal">Ding X, Yin B, Qian L, Zeng Z, Yang Z, Li H, et al. Screening for novel quorum-sensing inhibitors to interfere with the formation of <italic>Pseudomonas aeruginosa</italic> biofilm. J Med Microbiol. 2011;60(12):1827&#x02013;34.<pub-id pub-id-type="pmid">21852522</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>De Kievit</surname><given-names>T</given-names></name></person-group><article-title>Quorum sensing in Pseudomonas aeruginosa biofilms</article-title><source>Environ Microbiol</source><year>2009</year><volume>11</volume><issue>2</issue><fpage>279</fpage><lpage>288</lpage><?supplied-pmid 19196266?><pub-id pub-id-type="pmid">19196266</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">De Kievit T. Quorum sensing in Pseudomonas aeruginosa biofilms. Environ Microbiol. 2009;11(2):279&#x02013;88.<pub-id pub-id-type="pmid">19196266</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Ates</surname><given-names>A</given-names></name><name><surname>Tastan</surname><given-names>C</given-names></name><name><surname>Ermertcan</surname><given-names>S</given-names></name></person-group><article-title>CRISPR-Cas9-mediated targeting of multidrug resistance genes in methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>CRISPR J</source><year>2024</year><volume>7</volume><issue>6</issue><fpage>374</fpage><lpage>384</lpage><?supplied-pmid 39514329?><pub-id pub-id-type="pmid">39514329</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Ates A, Tastan C, Ermertcan S. CRISPR-Cas9-mediated targeting of multidrug resistance genes in methicillin-resistant <italic>Staphylococcus aureus</italic>. CRISPR J. 2024;7(6):374&#x02013;84.<pub-id pub-id-type="pmid">39514329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name><surname>Agha</surname><given-names>ASA</given-names></name><name><surname>Al-Samydai</surname><given-names>A</given-names></name><name><surname>Aburjai</surname><given-names>T</given-names></name></person-group><article-title>New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14</article-title><source>Heliyon</source><year>2025</year><volume>11</volume><fpage>e42013</fpage><pub-id pub-id-type="pmid">39906792</pub-id>
</element-citation><mixed-citation id="mc-CR112" publication-type="journal">Agha ASA, Al-Samydai A, Aburjai T. New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14. Heliyon. 2025;11:e42013.<pub-id pub-id-type="pmid">39906792</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>GJ</given-names></name><name><surname>Doudna</surname><given-names>JA</given-names></name></person-group><article-title>CRISPR-Cas guides the future of genetic engineering</article-title><source>Science</source><year>2018</year><volume>361</volume><issue>6405</issue><fpage>866</fpage><lpage>869</lpage><?supplied-pmid 30166482?><pub-id pub-id-type="pmid">30166482</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science. 2018;361(6405):866&#x02013;9.<pub-id pub-id-type="pmid">30166482</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Gholizadeh</surname><given-names>P</given-names></name><name><surname>Aghazadeh</surname><given-names>M</given-names></name><name><surname>Ghotaslou</surname><given-names>R</given-names></name><name><surname>Rezaee</surname><given-names>MA</given-names></name><name><surname>Pirzadeh</surname><given-names>T</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><etal/></person-group><article-title>Role of CRISPR-Cas system on antibiotic resistance patterns of Enterococcus faecalis</article-title><source>Ann Clin Microbiol Antimicrob</source><year>2021</year><volume>20</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">33402178</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Gholizadeh P, Aghazadeh M, Ghotaslou R, Rezaee MA, Pirzadeh T, Cui L, et al. Role of CRISPR-Cas system on antibiotic resistance patterns of Enterococcus faecalis. Ann Clin Microbiol Antimicrob. 2021;20:1&#x02013;12.<pub-id pub-id-type="pmid">33402178</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdul</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>M-R</given-names></name><name><surname>Zhong</surname><given-names>C-J</given-names></name><name><surname>Liu</surname><given-names>Y-Y</given-names></name><name><surname>Hou</surname><given-names>W</given-names></name><name><surname>Xiong</surname><given-names>H-R</given-names></name></person-group><article-title>An updated review on the antimicrobial and pharmacological properties of <italic>Uncaria</italic> (Rubiaceae)</article-title><source>J Herbal Med</source><year>2022</year><volume>34</volume><fpage>100573</fpage></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Abdul R, Wang M-R, Zhong C-J, Liu Y-Y, Hou W, Xiong H-R. An updated review on the antimicrobial and pharmacological properties of <italic>Uncaria</italic> (Rubiaceae). J Herbal Med. 2022;34:100573.</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name></person-group><article-title>CRISPR/Cas9 for genome editing: progress, implications and challenges</article-title><source>Hum Mol Genet</source><year>2014</year><volume>23</volume><issue>R1</issue><fpage>R40</fpage><lpage>R46</lpage><?supplied-pmid 24651067?><pub-id pub-id-type="pmid">24651067</pub-id>
</element-citation><mixed-citation id="mc-CR116" publication-type="journal">Zhang F, Wen Y, Guo X. CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet. 2014;23(R1):R40&#x02013;6.<pub-id pub-id-type="pmid">24651067</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S-W</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>Y-M</given-names></name><name><surname>Yi</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>J-C</given-names></name><name><surname>Huang</surname><given-names>X-Y</given-names></name><etal/></person-group><article-title>Current applications and future perspective of CRISPR/Cas9 gene editing in cancer</article-title><source>Mol Cancer</source><year>2022</year><volume>21</volume><issue>1</issue><fpage>57</fpage><?supplied-pmid 35189910?><pub-id pub-id-type="pmid">35189910</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">Wang S-W, Gao C, Zheng Y-M, Yi L, Lu J-C, Huang X-Y, et al. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer. 2022;21(1):57.<pub-id pub-id-type="pmid">35189910</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Savi&#x00107;</surname><given-names>N</given-names></name><name><surname>Schwank</surname><given-names>G</given-names></name></person-group><article-title>Advances in therapeutic CRISPR/Cas9 genome editing</article-title><source>Transl Res</source><year>2016</year><volume>168</volume><fpage>15</fpage><lpage>21</lpage><?supplied-pmid 26470680?><pub-id pub-id-type="pmid">26470680</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">Savi&#x00107; N, Schwank G. Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res. 2016;168:15&#x02013;21.<pub-id pub-id-type="pmid">26470680</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Makarova</surname><given-names>KS</given-names></name><name><surname>Wolf</surname><given-names>YI</given-names></name><name><surname>Alkhnbashi</surname><given-names>OS</given-names></name><name><surname>Costa</surname><given-names>F</given-names></name><name><surname>Shah</surname><given-names>SA</given-names></name><name><surname>Saunders</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>An updated evolutionary classification of CRISPR-Cas systems</article-title><source>Nat Rev Microbiol</source><year>2015</year><volume>13</volume><issue>11</issue><fpage>722</fpage><lpage>736</lpage><?supplied-pmid 26411297?><pub-id pub-id-type="pmid">26411297</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, et al. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol. 2015;13(11):722&#x02013;36.<pub-id pub-id-type="pmid">26411297</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name><surname>Makarova</surname><given-names>KS</given-names></name><name><surname>Wolf</surname><given-names>YI</given-names></name><name><surname>Iranzo</surname><given-names>J</given-names></name><name><surname>Shmakov</surname><given-names>SA</given-names></name><name><surname>Alkhnbashi</surname><given-names>OS</given-names></name><name><surname>Brouns</surname><given-names>SJJ</given-names></name><etal/></person-group><article-title>Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants</article-title><source>Nat Rev Microbiol</source><year>2020</year><volume>18</volume><issue>2</issue><fpage>67</fpage><lpage>83</lpage><?supplied-pmid 31857715?><pub-id pub-id-type="pmid">31857715</pub-id>
</element-citation><mixed-citation id="mc-CR120" publication-type="journal">Makarova KS, Wolf YI, Iranzo J, Shmakov SA, Alkhnbashi OS, Brouns SJJ, et al. Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol. 2020;18(2):67&#x02013;83.<pub-id pub-id-type="pmid">31857715</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name><surname>Morisaka</surname><given-names>H</given-names></name><name><surname>Yoshimi</surname><given-names>K</given-names></name><name><surname>Okuzaki</surname><given-names>Y</given-names></name><name><surname>Gee</surname><given-names>P</given-names></name><name><surname>Kunihiro</surname><given-names>Y</given-names></name><name><surname>Sonpho</surname><given-names>E</given-names></name><etal/></person-group><article-title>Crispr-Cas3 induces broad and unidirectional genome editing in human cells</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>5302</fpage><?supplied-pmid 31811138?><pub-id pub-id-type="pmid">31811138</pub-id>
</element-citation><mixed-citation id="mc-CR121" publication-type="journal">Morisaka H, Yoshimi K, Okuzaki Y, Gee P, Kunihiro Y, Sonpho E, et al. Crispr-Cas3 induces broad and unidirectional genome editing in human cells. Nat Commun. 2019;10(1):5302.<pub-id pub-id-type="pmid">31811138</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Rost&#x000f8;l</surname><given-names>JT</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Kuryavyi</surname><given-names>V</given-names></name><name><surname>Maguin</surname><given-names>P</given-names></name><name><surname>Kao</surname><given-names>K</given-names></name><name><surname>Froom</surname><given-names>R</given-names></name><etal/></person-group><article-title>The Card1 nuclease provides defence during type III CRISPR immunity</article-title><source>Nature</source><year>2021</year><volume>590</volume><issue>7847</issue><fpage>624</fpage><lpage>629</lpage><?supplied-pmid 33461211?><pub-id pub-id-type="pmid">33461211</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Rost&#x000f8;l JT, Xie W, Kuryavyi V, Maguin P, Kao K, Froom R, et al. The Card1 nuclease provides defence during type III CRISPR immunity. Nature. 2021;590(7847):624&#x02013;9.<pub-id pub-id-type="pmid">33461211</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Fuglsang</surname><given-names>A</given-names></name><name><surname>Kjeldsen</surname><given-names>AL</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Bhoobalan-Chitty</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name></person-group><article-title>DNA targeting by subtype I-D CRISPR-Cas shows type I and type III features</article-title><source>Nucleic Acids Res</source><year>2020</year><volume>48</volume><issue>18</issue><fpage>10470</fpage><lpage>10478</lpage><?supplied-pmid 32960267?><pub-id pub-id-type="pmid">32960267</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Lin J, Fuglsang A, Kjeldsen AL, Sun K, Bhoobalan-Chitty Y, Peng X. DNA targeting by subtype I-D CRISPR-Cas shows type I and type III features. Nucleic Acids Res. 2020;48(18):10470&#x02013;8.<pub-id pub-id-type="pmid">32960267</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>RN</given-names></name><name><surname>Golden</surname><given-names>SM</given-names></name><name><surname>van Erp</surname><given-names>PB</given-names></name><name><surname>Carter</surname><given-names>J</given-names></name><name><surname>Westra</surname><given-names>ER</given-names></name><name><surname>Brouns</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Structural biology. Crystal structure of the CRISPR RNA-guided surveillance complex from Escherichia coli</article-title><source>Science</source><year>2014</year><volume>345</volume><issue>6203</issue><fpage>1473</fpage><lpage>9</lpage><?supplied-pmid 25103409?><pub-id pub-id-type="pmid">25103409</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Jackson RN, Golden SM, van Erp PB, Carter J, Westra ER, Brouns SJ, et al. Structural biology. Crystal structure of the CRISPR RNA-guided surveillance complex from Escherichia coli. Science. 2014;345(6203):1473&#x02013;9.<pub-id pub-id-type="pmid">25103409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name><surname>Karneyeva</surname><given-names>K</given-names></name><name><surname>Kolesnik</surname><given-names>M</given-names></name><name><surname>Livenskyi</surname><given-names>A</given-names></name><name><surname>Zgoda</surname><given-names>V</given-names></name><name><surname>Zubarev</surname><given-names>V</given-names></name><name><surname>Trofimova</surname><given-names>A</given-names></name><etal/></person-group><article-title>Interference requirements of type III CRISPR-Cas systems from <italic>Thermus thermophilus</italic></article-title><source>J Mol Biol</source><year>2024</year><volume>436</volume><issue>6</issue><fpage>168448</fpage><?supplied-pmid 38266982?><pub-id pub-id-type="pmid">38266982</pub-id>
</element-citation><mixed-citation id="mc-CR125" publication-type="journal">Karneyeva K, Kolesnik M, Livenskyi A, Zgoda V, Zubarev V, Trofimova A, et al. Interference requirements of type III CRISPR-Cas systems from <italic>Thermus thermophilus</italic>. J Mol Biol. 2024;436(6):168448.<pub-id pub-id-type="pmid">38266982</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>Rost&#x000f8;l</surname><given-names>JT</given-names></name><name><surname>Marraffini</surname><given-names>LA</given-names></name></person-group><article-title>Non-specific degradation of transcripts promotes plasmid clearance during type III-A CRISPR-Cas immunity</article-title><source>Nat Microbiol</source><year>2019</year><volume>4</volume><issue>4</issue><fpage>656</fpage><lpage>662</lpage><?supplied-pmid 30692669?><pub-id pub-id-type="pmid">30692669</pub-id>
</element-citation><mixed-citation id="mc-CR126" publication-type="journal">Rost&#x000f8;l JT, Marraffini LA. Non-specific degradation of transcripts promotes plasmid clearance during type III-A CRISPR-Cas immunity. Nat Microbiol. 2019;4(4):656&#x02013;62.<pub-id pub-id-type="pmid">30692669</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>Koonin</surname><given-names>EV</given-names></name><name><surname>Makarova</surname><given-names>KS</given-names></name></person-group><article-title>Origins and evolution of CRISPR-Cas systems</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>2019</year><volume>374</volume><issue>1772</issue><fpage>20180087</fpage><?supplied-pmid 30905284?><pub-id pub-id-type="pmid">30905284</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">Koonin EV, Makarova KS. Origins and evolution of CRISPR-Cas systems. Philos Trans R Soc Lond B Biol Sci. 2019;374(1772):20180087.<pub-id pub-id-type="pmid">30905284</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name><surname>Moya-Beltr&#x000e1;n</surname><given-names>A</given-names></name><name><surname>Makarova</surname><given-names>KS</given-names></name><name><surname>Acu&#x000f1;a</surname><given-names>LG</given-names></name><name><surname>Wolf</surname><given-names>YI</given-names></name><name><surname>Covarrubias</surname><given-names>PC</given-names></name><name><surname>Shmakov</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Evolution of type IV CRISPR-Cas systems: insights from CRISPR loci in integrative conjugative elements of Acidithiobacillia</article-title><source>Crispr j</source><year>2021</year><volume>4</volume><issue>5</issue><fpage>656</fpage><lpage>672</lpage><?supplied-pmid 34582696?><pub-id pub-id-type="pmid">34582696</pub-id>
</element-citation><mixed-citation id="mc-CR128" publication-type="journal">Moya-Beltr&#x000e1;n A, Makarova KS, Acu&#x000f1;a LG, Wolf YI, Covarrubias PC, Shmakov SA, et al. Evolution of type IV CRISPR-Cas systems: insights from CRISPR loci in integrative conjugative elements of Acidithiobacillia. Crispr j. 2021;4(5):656&#x02013;72.<pub-id pub-id-type="pmid">34582696</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name><surname>Pinilla-Redondo</surname><given-names>R</given-names></name><name><surname>Mayo-Mu&#x000f1;oz</surname><given-names>D</given-names></name><name><surname>Russel</surname><given-names>J</given-names></name><name><surname>Garrett</surname><given-names>RA</given-names></name><name><surname>Randau</surname><given-names>L</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Type IV CRISPR-Cas systems are highly diverse and involved in competition between plasmids</article-title><source>Nucleic Acids Res</source><year>2020</year><volume>48</volume><issue>4</issue><fpage>2000</fpage><lpage>2012</lpage><?supplied-pmid 31879772?><pub-id pub-id-type="pmid">31879772</pub-id>
</element-citation><mixed-citation id="mc-CR129" publication-type="journal">Pinilla-Redondo R, Mayo-Mu&#x000f1;oz D, Russel J, Garrett RA, Randau L, S&#x000f8;rensen SJ, et al. Type IV CRISPR-Cas systems are highly diverse and involved in competition between plasmids. Nucleic Acids Res. 2020;48(4):2000&#x02013;12.<pub-id pub-id-type="pmid">31879772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name><surname>Faure</surname><given-names>G</given-names></name><name><surname>Makarova</surname><given-names>KS</given-names></name><name><surname>Koonin</surname><given-names>EV</given-names></name></person-group><article-title>CRISPR-Cas: complex functional networks and multiple roles beyond adaptive immunity</article-title><source>J Mol Biol</source><year>2019</year><volume>431</volume><issue>1</issue><fpage>3</fpage><lpage>20</lpage><?supplied-pmid 30193985?><pub-id pub-id-type="pmid">30193985</pub-id>
</element-citation><mixed-citation id="mc-CR130" publication-type="journal">Faure G, Makarova KS, Koonin EV. CRISPR-Cas: complex functional networks and multiple roles beyond adaptive immunity. J Mol Biol. 2019;431(1):3&#x02013;20.<pub-id pub-id-type="pmid">30193985</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>F</given-names></name><name><surname>Doudna</surname><given-names>JA</given-names></name></person-group><article-title>CRISPR-Cas9 structures and mechanisms</article-title><source>Annu Rev Biophys</source><year>2017</year><volume>46</volume><fpage>505</fpage><lpage>529</lpage><?supplied-pmid 28375731?><pub-id pub-id-type="pmid">28375731</pub-id>
</element-citation><mixed-citation id="mc-CR131" publication-type="journal">Jiang F, Doudna JA. CRISPR-Cas9 structures and mechanisms. Annu Rev Biophys. 2017;46:505&#x02013;29.<pub-id pub-id-type="pmid">28375731</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Shmakov</surname><given-names>S</given-names></name><name><surname>Smargon</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>D</given-names></name><name><surname>Cox</surname><given-names>D</given-names></name><name><surname>Pyzocha</surname><given-names>N</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><etal/></person-group><article-title>Diversity and evolution of class 2 CRISPR-Cas systems</article-title><source>Nat Rev Microbiol</source><year>2017</year><volume>15</volume><issue>3</issue><fpage>169</fpage><lpage>182</lpage><?supplied-pmid 28111461?><pub-id pub-id-type="pmid">28111461</pub-id>
</element-citation><mixed-citation id="mc-CR132" publication-type="journal">Shmakov S, Smargon A, Scott D, Cox D, Pyzocha N, Yan W, et al. Diversity and evolution of class 2 CRISPR-Cas systems. Nat Rev Microbiol. 2017;15(3):169&#x02013;82.<pub-id pub-id-type="pmid">28111461</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Yosef</surname><given-names>I</given-names></name><name><surname>Goren</surname><given-names>MG</given-names></name><name><surname>Qimron</surname><given-names>U</given-names></name></person-group><article-title>Proteins and DNA elements essential for the CRISPR adaptation process in <italic>Escherichia coli</italic></article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><issue>12</issue><fpage>5569</fpage><lpage>5576</lpage><?supplied-pmid 22402487?><pub-id pub-id-type="pmid">22402487</pub-id>
</element-citation><mixed-citation id="mc-CR133" publication-type="journal">Yosef I, Goren MG, Qimron U. Proteins and DNA elements essential for the CRISPR adaptation process in <italic>Escherichia coli</italic>. Nucleic Acids Res. 2012;40(12):5569&#x02013;76.<pub-id pub-id-type="pmid">22402487</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name><surname>Bikard</surname><given-names>D</given-names></name><name><surname>Euler</surname><given-names>CW</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Nussenzweig</surname><given-names>PM</given-names></name><name><surname>Goldberg</surname><given-names>GW</given-names></name><name><surname>Duportet</surname><given-names>X</given-names></name><etal/></person-group><article-title>Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials</article-title><source>Nat Biotechnol</source><year>2014</year><volume>32</volume><issue>11</issue><fpage>1146</fpage><lpage>1150</lpage><?supplied-pmid 25282355?><pub-id pub-id-type="pmid">25282355</pub-id>
</element-citation><mixed-citation id="mc-CR134" publication-type="journal">Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014;32(11):1146&#x02013;50.<pub-id pub-id-type="pmid">25282355</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name><surname>Doudna</surname><given-names>JA</given-names></name><name><surname>Charpentier</surname><given-names>E</given-names></name></person-group><article-title>Genome editing. The new frontier of genome engineering with CRISPR-Cas9</article-title><source>Science</source><year>2014</year><volume>346</volume><issue>6213</issue><fpage>1258096</fpage><?supplied-pmid 25430774?><pub-id pub-id-type="pmid">25430774</pub-id>
</element-citation><mixed-citation id="mc-CR135" publication-type="journal">Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.<pub-id pub-id-type="pmid">25430774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name><surname>Ledford</surname><given-names>H</given-names></name></person-group><article-title>Major CRISPR patent decision won't end tangled dispute</article-title><source>Nature</source><year>2022</year><volume>603</volume><issue>7901</issue><fpage>373</fpage><lpage>374</lpage><?supplied-pmid 35264807?><pub-id pub-id-type="pmid">35264807</pub-id>
</element-citation><mixed-citation id="mc-CR136" publication-type="journal">Ledford H. Major CRISPR patent decision won&#x02019;t end tangled dispute. Nature. 2022;603(7901):373&#x02013;4.<pub-id pub-id-type="pmid">35264807</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name><surname>Koonin</surname><given-names>EV</given-names></name><name><surname>Makarova</surname><given-names>KS</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><article-title>Diversity, classification and evolution of CRISPR-Cas systems</article-title><source>Curr Opin Microbiol</source><year>2017</year><volume>37</volume><fpage>67</fpage><lpage>78</lpage><?supplied-pmid 28605718?><pub-id pub-id-type="pmid">28605718</pub-id>
</element-citation><mixed-citation id="mc-CR137" publication-type="journal">Koonin EV, Makarova KS, Zhang F. Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol. 2017;37:67&#x02013;78.<pub-id pub-id-type="pmid">28605718</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>WX</given-names></name><name><surname>Hunnewell</surname><given-names>P</given-names></name><name><surname>Alfonse</surname><given-names>LE</given-names></name><name><surname>Carte</surname><given-names>JM</given-names></name><name><surname>Keston-Smith</surname><given-names>E</given-names></name><name><surname>Sothiselvam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Functionally diverse type V CRISPR-Cas systems</article-title><source>Science</source><year>2019</year><volume>363</volume><issue>6422</issue><fpage>88</fpage><lpage>91</lpage><?supplied-pmid 30523077?><pub-id pub-id-type="pmid">30523077</pub-id>
</element-citation><mixed-citation id="mc-CR138" publication-type="journal">Yan WX, Hunnewell P, Alfonse LE, Carte JM, Keston-Smith E, Sothiselvam S, et al. Functionally diverse type V CRISPR-Cas systems. Science. 2019;363(6422):88&#x02013;91.<pub-id pub-id-type="pmid">30523077</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JS</given-names></name><name><surname>Ma</surname><given-names>E</given-names></name><name><surname>Harrington</surname><given-names>LB</given-names></name><name><surname>Da Costa</surname><given-names>M</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Palefsky</surname><given-names>JM</given-names></name><etal/></person-group><article-title>CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity</article-title><source>Science</source><year>2018</year><volume>360</volume><issue>6387</issue><fpage>436</fpage><lpage>439</lpage><?supplied-pmid 29449511?><pub-id pub-id-type="pmid">29449511</pub-id>
</element-citation><mixed-citation id="mc-CR139" publication-type="journal">Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science. 2018;360(6387):436&#x02013;9.<pub-id pub-id-type="pmid">29449511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>SY</given-names></name><name><surname>Cheng</surname><given-names>QX</given-names></name><name><surname>Wang</surname><given-names>JM</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Zhang</surname><given-names>ZL</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><etal/></person-group><article-title>CRISPR-Cas12a-assisted nucleic acid detection</article-title><source>Cell Discov</source><year>2018</year><volume>4</volume><fpage>20</fpage><?supplied-pmid 29707234?><pub-id pub-id-type="pmid">29707234</pub-id>
</element-citation><mixed-citation id="mc-CR140" publication-type="journal">Li SY, Cheng QX, Wang JM, Li XY, Zhang ZL, Gao S, et al. CRISPR-Cas12a-assisted nucleic acid detection. Cell Discov. 2018;4:20.<pub-id pub-id-type="pmid">29707234</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><etal/></person-group><article-title>HOLMESv2: a CRISPR-Cas12b-assisted platform for nucleic acid detection and DNA methylation quantitation</article-title><source>ACS Synth Biol</source><year>2019</year><volume>8</volume><issue>10</issue><fpage>2228</fpage><lpage>2237</lpage><?supplied-pmid 31532637?><pub-id pub-id-type="pmid">31532637</pub-id>
</element-citation><mixed-citation id="mc-CR141" publication-type="journal">Li L, Li S, Wu N, Wu J, Wang G, Zhao G, et al. HOLMESv2: a CRISPR-Cas12b-assisted platform for nucleic acid detection and DNA methylation quantitation. ACS Synth Biol. 2019;8(10):2228&#x02013;37.<pub-id pub-id-type="pmid">31532637</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name><surname>Broughton</surname><given-names>JP</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Fasching</surname><given-names>CL</given-names></name><name><surname>Servellita</surname><given-names>V</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><etal/></person-group><article-title>CRISPR-Cas12-based detection of SARS-CoV-2</article-title><source>Nat Biotechnol</source><year>2020</year><volume>38</volume><issue>7</issue><fpage>870</fpage><lpage>874</lpage><?supplied-pmid 32300245?><pub-id pub-id-type="pmid">32300245</pub-id>
</element-citation><mixed-citation id="mc-CR142" publication-type="journal">Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020;38(7):870&#x02013;4.<pub-id pub-id-type="pmid">32300245</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><mixed-citation publication-type="other">Rananaware SR, Meister KS, Shoemaker GM, Vesco EK, Sandoval LSW, Lewis JG, et al. PAM-free diagnostics with diverse type V CRISPR-Cas systems. medRxiv. 2024.</mixed-citation></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name><surname>Kordy&#x0015b;</surname><given-names>M</given-names></name><name><surname>Sen</surname><given-names>R</given-names></name><name><surname>Warkocki</surname><given-names>Z</given-names></name></person-group><article-title>Applications of the versatile CRISPR-Cas13 RNA targeting system</article-title><source>WIREs RNA</source><year>2022</year><volume>13</volume><issue>3</issue><fpage>e1694</fpage><?supplied-pmid 34553495?><pub-id pub-id-type="pmid">34553495</pub-id>
</element-citation><mixed-citation id="mc-CR144" publication-type="journal">Kordy&#x0015b; M, Sen R, Warkocki Z. Applications of the versatile CRISPR-Cas13 RNA targeting system. WIREs RNA. 2022;13(3):e1694.<pub-id pub-id-type="pmid">34553495</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connell</surname><given-names>MR</given-names></name></person-group><article-title>Molecular mechanisms of RNA targeting by Cas13-containing type VI CRISPR-Cas systems</article-title><source>J Mol Biol</source><year>2019</year><volume>431</volume><issue>1</issue><fpage>66</fpage><lpage>87</lpage><?supplied-pmid 29940185?><pub-id pub-id-type="pmid">29940185</pub-id>
</element-citation><mixed-citation id="mc-CR145" publication-type="journal">O&#x02019;Connell MR. Molecular mechanisms of RNA targeting by Cas13-containing type VI CRISPR-Cas systems. J Mol Biol. 2019;431(1):66&#x02013;87.<pub-id pub-id-type="pmid">29940185</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name><surname>Abudayyeh</surname><given-names>OO</given-names></name><name><surname>Gootenberg</surname><given-names>JS</given-names></name><name><surname>Konermann</surname><given-names>S</given-names></name><name><surname>Joung</surname><given-names>J</given-names></name><name><surname>Slaymaker</surname><given-names>IM</given-names></name><name><surname>Cox</surname><given-names>DB</given-names></name><etal/></person-group><article-title>C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector</article-title><source>Science</source><year>2016</year><volume>353</volume><issue>6299</issue><fpage>aaf5573</fpage><?supplied-pmid 27256883?><pub-id pub-id-type="pmid">27256883</pub-id>
</element-citation><mixed-citation id="mc-CR146" publication-type="journal">Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, Cox DB, et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science. 2016;353(6299):aaf5573.<pub-id pub-id-type="pmid">27256883</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name><surname>Gootenberg</surname><given-names>JS</given-names></name><name><surname>Abudayyeh</surname><given-names>OO</given-names></name><name><surname>Kellner</surname><given-names>MJ</given-names></name><name><surname>Joung</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><article-title>Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6</article-title><source>Science</source><year>2018</year><volume>360</volume><issue>6387</issue><fpage>439</fpage><lpage>444</lpage><?supplied-pmid 29449508?><pub-id pub-id-type="pmid">29449508</pub-id>
</element-citation><mixed-citation id="mc-CR147" publication-type="journal">Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science. 2018;360(6387):439&#x02013;44.<pub-id pub-id-type="pmid">29449508</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name><surname>Abudayyeh</surname><given-names>OO</given-names></name><name><surname>Gootenberg</surname><given-names>JS</given-names></name><name><surname>Essletzbichler</surname><given-names>P</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Joung</surname><given-names>J</given-names></name><name><surname>Belanto</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>RNA targeting with CRISPR-Cas13</article-title><source>Nature</source><year>2017</year><volume>550</volume><issue>7675</issue><fpage>280</fpage><lpage>284</lpage><?supplied-pmid 28976959?><pub-id pub-id-type="pmid">28976959</pub-id>
</element-citation><mixed-citation id="mc-CR148" publication-type="journal">Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, et al. RNA targeting with CRISPR-Cas13. Nature. 2017;550(7675):280&#x02013;4.<pub-id pub-id-type="pmid">28976959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name><surname>Kellner</surname><given-names>MJ</given-names></name><name><surname>Koob</surname><given-names>JG</given-names></name><name><surname>Gootenberg</surname><given-names>JS</given-names></name><name><surname>Abudayyeh</surname><given-names>OO</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><article-title>SHERLOCK: nucleic acid detection with CRISPR nucleases</article-title><source>Nat Protoc</source><year>2019</year><volume>14</volume><issue>10</issue><fpage>2986</fpage><lpage>3012</lpage><?supplied-pmid 31548639?><pub-id pub-id-type="pmid">31548639</pub-id>
</element-citation><mixed-citation id="mc-CR149" publication-type="journal">Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc. 2019;14(10):2986&#x02013;3012.<pub-id pub-id-type="pmid">31548639</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name><surname>Altae-Tran</surname><given-names>H</given-names></name><name><surname>Kannan</surname><given-names>S</given-names></name><name><surname>Suberski</surname><given-names>AJ</given-names></name><name><surname>Mears</surname><given-names>KS</given-names></name><name><surname>Demircioglu</surname><given-names>FE</given-names></name><name><surname>Moeller</surname><given-names>L</given-names></name><etal/></person-group><article-title>Uncovering the functional diversity of rare CRISPR-Cas systems with deep terascale clustering</article-title><source>Science</source><year>2023</year><volume>382</volume><issue>6673</issue><fpage>eadi1910</fpage><?supplied-pmid 37995242?><pub-id pub-id-type="pmid">37995242</pub-id>
</element-citation><mixed-citation id="mc-CR150" publication-type="journal">Altae-Tran H, Kannan S, Suberski AJ, Mears KS, Demircioglu FE, Moeller L, et al. Uncovering the functional diversity of rare CRISPR-Cas systems with deep terascale clustering. Science. 2023;382(6673):eadi1910.<pub-id pub-id-type="pmid">37995242</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name><surname>Smargon</surname><given-names>AA</given-names></name><name><surname>Cox</surname><given-names>DBT</given-names></name><name><surname>Pyzocha</surname><given-names>NK</given-names></name><name><surname>Zheng</surname><given-names>K</given-names></name><name><surname>Slaymaker</surname><given-names>IM</given-names></name><name><surname>Gootenberg</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28</article-title><source>Mol Cell</source><year>2017</year><volume>65</volume><issue>4</issue><fpage>618</fpage><lpage>30.e7</lpage><?supplied-pmid 28065598?><pub-id pub-id-type="pmid">28065598</pub-id>
</element-citation><mixed-citation id="mc-CR151" publication-type="journal">Smargon AA, Cox DBT, Pyzocha NK, Zheng K, Slaymaker IM, Gootenberg JS, et al. Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28. Mol Cell. 2017;65(4):618-30.e7.<pub-id pub-id-type="pmid">28065598</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>T</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name></person-group><article-title>Advances in the RNA-targeting CRISPR-Cas systems</article-title><source>Sheng Wu Gong Cheng Xue Bao</source><year>2023</year><volume>39</volume><issue>4</issue><fpage>1363</fpage><lpage>1373</lpage><?supplied-pmid 37154311?><pub-id pub-id-type="pmid">37154311</pub-id>
</element-citation><mixed-citation id="mc-CR152" publication-type="journal">Hong T, Luo Q. Advances in the RNA-targeting CRISPR-Cas systems. Sheng Wu Gong Cheng Xue Bao. 2023;39(4):1363&#x02013;73.<pub-id pub-id-type="pmid">37154311</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name><surname>Per&#x0010d;ulija</surname><given-names>V</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Ouyang</surname><given-names>S</given-names></name></person-group><article-title>Functional features and current applications of the RNA-targeting type VI CRISPR-Cas systems</article-title><source>Adv Sci</source><year>2021</year><volume>8</volume><issue>13</issue><fpage>2004685</fpage></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Per&#x0010d;ulija V, Lin J, Zhang B, Ouyang S. Functional features and current applications of the RNA-targeting type VI CRISPR-Cas systems. Adv Sci. 2021;8(13):2004685.</mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>WX</given-names></name><name><surname>Chong</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Makarova</surname><given-names>KS</given-names></name><name><surname>Koonin</surname><given-names>EV</given-names></name><name><surname>Cheng</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein</article-title><source>Mol Cell</source><year>2018</year><volume>70</volume><issue>2</issue><fpage>327</fpage><lpage>39.e5</lpage><?supplied-pmid 29551514?><pub-id pub-id-type="pmid">29551514</pub-id>
</element-citation><mixed-citation id="mc-CR154" publication-type="journal">Yan WX, Chong S, Zhang H, Makarova KS, Koonin EV, Cheng DR, et al. Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein. Mol Cell. 2018;70(2):327-39.e5.<pub-id pub-id-type="pmid">29551514</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto-Alphandary</surname><given-names>H</given-names></name><name><surname>Andremont</surname><given-names>A</given-names></name><name><surname>Couvreur</surname><given-names>P</given-names></name></person-group><article-title>Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications</article-title><source>Int J Antimicrob Agents</source><year>2000</year><volume>13</volume><issue>3</issue><fpage>155</fpage><lpage>168</lpage><?supplied-pmid 10724019?><pub-id pub-id-type="pmid">10724019</pub-id>
</element-citation><mixed-citation id="mc-CR155" publication-type="journal">Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents. 2000;13(3):155&#x02013;68.<pub-id pub-id-type="pmid">10724019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name><surname>Tyagi</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>P-C</given-names></name><name><surname>Chancellor</surname><given-names>M</given-names></name><name><surname>Yoshimura</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>Recent advances in intravesical drug/gene delivery</article-title><source>Mol Pharm</source><year>2006</year><volume>3</volume><issue>4</issue><fpage>369</fpage><lpage>379</lpage><?supplied-pmid 16889430?><pub-id pub-id-type="pmid">16889430</pub-id>
</element-citation><mixed-citation id="mc-CR156" publication-type="journal">Tyagi P, Wu P-C, Chancellor M, Yoshimura N, Huang L. Recent advances in intravesical drug/gene delivery. Mol Pharm. 2006;3(4):369&#x02013;79.<pub-id pub-id-type="pmid">16889430</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>L&#x000fc;</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name></person-group><article-title>Research progress on nucleic acid detection and genome editing of CRISPR/Cas12 system</article-title><source>Mol Biol Rep</source><year>2023</year><volume>50</volume><issue>4</issue><fpage>3723</fpage><lpage>3738</lpage><?supplied-pmid 36648696?><pub-id pub-id-type="pmid">36648696</pub-id>
</element-citation><mixed-citation id="mc-CR157" publication-type="journal">Yang Y, Wang D, L&#x000fc; P, Ma S, Chen K. Research progress on nucleic acid detection and genome editing of CRISPR/Cas12 system. Mol Biol Rep. 2023;50(4):3723&#x02013;38.<pub-id pub-id-type="pmid">36648696</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name><surname>Doudna</surname><given-names>JA</given-names></name><name><surname>Charpentier</surname><given-names>E</given-names></name></person-group><article-title>The new frontier of genome engineering with CRISPR-Cas9</article-title><source>Science</source><year>2014</year><volume>346</volume><issue>6213</issue><fpage>1258096</fpage><?supplied-pmid 25430774?><pub-id pub-id-type="pmid">25430774</pub-id>
</element-citation><mixed-citation id="mc-CR158" publication-type="journal">Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.<pub-id pub-id-type="pmid">25430774</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>